USPatent applicationPatented

Amino acid N-carboxyanhydrides with acyl substituents on nitrogen atoms thereof

Granted 30 Dec 2003 · 2 office actions

Life of the application

10 dated events
⤢ drag to zoom20022004200620082010201220142016201820202022ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

This invention provides amino acid N-carboxyanhydrides, each of which has an N-acyl substituent on its nitrogen atom, is represented by the following formula (1): readily reacts with nucleophilic reagents such as free amino acids, alcohols, anions or the like, and are intermediates useful for the high-yield production of amino acid derivatives, optically active compounds, peptides, polypeptides and the like useful in many fields lead by the fields of pharmaceuticals and agrochemicals, and also provides a process for the production of the amino acid N-carboxyanhydrides. Further, the present invention also provides a process for the production of diamides, which uses the compounds of the formula (1) and amine derivatives represented by the following formula (7): These diamides can also be suitably used for the production of amino acid derivatives, optically active compounds, peptides, polypeptides and the like.

Description

32 parts
›TECHNICAL FIELD

This invention relates to activated amino acid derivatives which are important intermediates useful in many fields led by the fields of pharmaceuticals and agrochemicals. The present invention is also concerned with novel amino acid N-carboxyanhydrides each of which has a substituent of the N-acyl type on a nitrogen atom thereof, and also with a process for the production of diamides, which makes use of the amino acid N-carboxyanhydrides, requires fewer steps and is economical.

›BACKGROUND ART · 1 of 3

Amino acids are available rather readily at low prices and have diverse structures and asymmetric carbon atoms, so that they have been widely used for many years as raw materials or the like for a variety of optically active compounds led by peptides. In particular, production technology of peptides, which uses amino acids as raw materials, has been one of important basic technologies for many years in many fields led by the fields of pharmaceuticals and agrochemicals. Keeping in step with the advance of molecular biology in recent years, the importance of peptides tends to increase progressively. There is, accordingly, an outstanding demand for an economical production process of peptides, which is suited for industrial practice on large scale.

The principle of peptide production resides a reaction in which a carboxyl group of an amino acid and an amino group of an amine derivative, which may be an amino acid, are subjected to dehydrating condensation to form an amide bond. In practice, however, a free amino acid becomes an ampholytic ion, forms an internal salt and is stabilized, so that the above-mentioned reaction does not occur spontaneously. Even if the reaction should proceed, high-yield production of a specific target product cannot be expected because the amino groups contained in the respective reactants are free and many dipeptides, diketopiperazine derivatives and the like are hence byproduced.

To obtain the target peptide with good yield, functional groups other than those needed have to be masked beforehand to prevent occurrence of undesired reactions. In the case of a methyl ester or the like, its reaction velocity is low and impractical so that a carboxyl component must be activated suitably. A protecting group used as a mask not only plays a role to prevent a side reaction but also has an effect to reduce the polarity of the amino acid and to render it more readily soluble in an organic solvent.

Examples of the protecting group can include urethane-type protecting groups such as tert-butoxycarbonyl (Boc) group and benzyloxycarbonyl (Z) group, alkyl-type protecting groups such as trityl group, and acyl-type protecting groups such as formyl group, tosyl group, acetyl group and benzoyl group. In these protecting groups, urethane-type protecting groups can hardly induce racemization [Jiro Yajima, Yuki Gosei Kyokai Shi (Journal of Synthetic Organic Chemistry, Japan), 29, 27 (1971); Noboru Yanaihara, Pharmacia, 7, 721 (1972)], but acyl-type and alkyl-type protecting groups are accompanied by a drawback that they tend to induce racemization. Further, alkyl-type protecting groups do not fully mask the basicity of an amino group so that the amino group may still be subjected to further acylation. With a trityl group, no second acylation can take place owing to its steric hindrance. Conversely, this steric hindrance makes it difficult to achieve introduction itself of a trityl group, and further, it is not easy to conduct a condensation reaction between a trityl-protected amino acid with and a trityl-protected amine.

A synthesis process which includes introduction of protecting groups requires protecting and deprotecting steps, each of which requires a costly reagent, and also purification steps after the protecting and deprotecting groups, respectively. This synthesis process, therefore, results in multi-step production, leading to an increase in cost.

If it is difficult to allow a condensation reaction to proceed easily between an amino acid and an amine, there are processes in each of which a carboxyl group of an amino acid derivative with a protected amino group is activated by an electron-attracting substituent to facilitate its nucleophilic attack on the carbon atom of a carbonyl group of the amine. Illustrative of these processes are the acid chloride process in which an activated amino acid is derived using PCl 5 , PCl 3 or thionyl chloride, the azidation process in which an activated amino acid is derived from an amino acid ester or the like via a hydrazide, the mixed acid anhydride process in which an activated amino acid is derived from a protected amino acid and another acid, and the crosslinking process making use of a conventional condensing agent such as N,N′-dicyclohexylcarbodiimide (DCC) or 1,1-carbonyl-diimidazole (hereinafter abbreviated as “CDI”). However, the acid chloride process involves a problem that many side reactions occur, the azidation process is accompanied by a problem that the derivation into an azide is very cumbersome, and the mixed acid anhydride process has a problem that disproportionation tends to occur when the temperature rises (“Peptide Synthesis” written by Nobuo Izumiya et al.). The process making use of a condensing agent is also accompanied by some drawbacks. In the case of DCC, for example, an acylisourea which is an intermediate formed by a reaction between a carboxyl group and DCC may undergo an intermolecular rearrangement in the presence of a base to form an acylurea, thereby lowering the yield of the target product or making it difficult to separate the acylurea from the target product. Further, DCC dehydrates the ω-amide of asparagine or glutamine to form a nitrile. On the other hand, CDI is an expensive reagent, and the crosslinking process making use of CDI is not considered to be an economical production process of peptides.

As described above, many peptide production processes have been studied. To be industrially stable production technology or low-cost production technology, however, these processes have to be considered to be still insufficient.

On the other hand, amino acid N-carboxyanhydrides (referred to as “NCAs” when abbreviated) which have been studied as active amino acids readily react with most free amines. Primary merits of NCAs include that they themselves are effective acylating agents (“Peptides”, 9, 83) and that they permit more economical production through fewer steps than the commonly-employed crosslinking process making use of a condensing agent such as N,N-dicyclohexylcarbodiimide or 1,1-carbonyldiimidazole or the N-hydroxysuccinimide ester crosslinking process. In addition, these amino acid NCAs do not develop the problem of racemization or the like of amino acids under reaction conditions commonly employed for the production of peptides. NCAs have, therefore, been expected for many years to serve as important intermediates for the synthesis of peptides [Pheiol Chem., 147, 91 (1926)].

›BACKGROUND ART · 2 of 3

The peptide synthesis which uses an N-unsubstituted NCA as a production intermediate and has been known well for many years, however, involves many problems in that side reactions such as a polymerization reaction are always hardly controllable and the reactivity and stability differ depending on the kinds of the reactants. This peptide synthesis, therefore, has not been considered as a common peptide production process although its potential utility has been recognized. With a view to solving these problems, numerous improvements have been made. For example, Bailey et al. reported an illustrative condensation reaction between L-alanine-NCA and glycine under low temperature (−40° C.) conditions in an organic solvent [J. Chem. Soc., 8461 (1950)]. Further, Robert G. D. et al. reported illustrative production of a dipeptide under 0 to 5° C. conditions in an aqueous solution (around pH 10) by using L-phenylalaline-NCA [J. Am. Chem. Soc., 88, 3163 (1966)]. In addition, Thomas J. B. et al. reported potential industrial utility of a condensation reaction making use of L-alanine-NCA and L-proline [J. Org. Chem., 53, 836 (1988)].

Despite these efforts, however, N-unsubstituted NCAs are very limited in conditions optimal for the prevention of a polymerization reaction and racemization reaction as side reactions and are not suited from the industrial viewpoint.

Accordingly, efforts have been made in attempts to solve problems in polymerization control and the like by introducing a substituent of the N-alkyl or N-sulfenyl type onto a nitrogen atom of an NCA. Reported in patents and other technical publications include, for example, N-methyl-NCA, N-ethyl-NCA, N-nitrophenylsulfenyl-NCA [Kricheldorf et al., Angew. Chem. Acta 85, (1978) 86], N-xanthyl-NCA [Halstroem and Kovacs et al., Acta Chemica Scandvnavia, Ser. B, 1986, BYO(6), 462; U.S. Pat. No. 4,267,344], and N-trityl-NCA (Block and Cox et al., “Peptides, Proc. of the 5 th Europ. Symp., Oxford, September 1962, Pergramon Press 1963, Compiled by G. T. Young, page 84”. However, production processes of these compounds themselves lack general applicability, and effects of these compounds for polymerization control and the like are not sufficient. These compounds, therefore, have not lead to solution of the fundamental problems.

In 1980's, it was attempted to control the reactivity of an NCA by introducing a trimethylsilyl group onto the nitrogen atom of the NCA. This control was practiced with glycine-NCA (Bayer AG, DE 1768871). This approach indicated possibility of suppressing a polymerization reaction which was considered to be one of serious side reactions, but involves a problem in stability and a problem of an increase in production cost, and its application to other amino acids has not been made since then. The idea of introducing a substituent onto a nitrogen atom was subsequently applied by Palomo C. et al. to a condensation reaction between a non-natural amino acid and an amine by using a NCA in which a nitrogen atom is protected by a benzyl group [Chem. Commun., 7, 691 (1997); Tetrahedron Lett., 38(17), 3093 (1997)]. However, these processes are also accompanied by problems in that the target NCA cannot be produced economically due to the need for many steps for its synthesis and a limitation is imposed on amino acids which can be synthesized.

In recent years, N-substituted NCAs with substituents of the urethane type as substituents on nitrogen atoms were reported. Firstly, Kricheldolf et al. reported a process for the production of N-methoxycarbonylglycine-NCA and N-ethoxycarbonylglycine-NCA [Macromol. Chem., 178, 905 (1977)]. Then, Fuller et al. reported production of N-urethane-substituted NCA and N-urethane-substituted thiocarboxylic acid anhydride from amino acids other than glycine (Bioresearch Inc., JP 2875834 B). They admirably solved the problem of polymerization control or the like by using these N-urethane-substituted NCAs. They, however, used costly N-urethane groups as amino-protecting groups, thereby failing to make good use of the merit of NCAs that amide compounds can be produced through fewer steps at low cost without using protecting groups. Further, they did not conduct any study on N-substituted NCAs other than N-urethane-substituted NCAs and made no mention about N-acyl-substituted NCAs.

An N-acyl-substituted NCA, on the other hand, is expected to provide a short and economical process for forming an amino acid into a derivative thereof because use of a target amide structure as a substituent in NCA prevents side reactions such as polymerization and obviates protection and deprotection. For example, a reaction with a desired amine has possibility of synthesizing a diamide compound at low cost without steps such as bonding and elimination of a protecting group to and from an amino group.

Only an extremely limited number of reports have, however, been made on the synthesis of N-acyl-substituted NCAs. Moreover, none of these synthesis processes are equipped with general applicability. For example, Kricheldolf et al. reported 3-(3,5-dinitrobenzoyl)-4,4-dimethyl-2,5-oxazolinedinedione in the article referred to in the above [Macromol. Chem., 178, 905 (1977)]. This is the only example reported by them concerning N-acyl-substituted NCAs. In addition, the amino acid employed in their report is di-substituted at the a-position and contains no asymmetric carbon atom, and their report does not disclose any N-acyl-substituted NCA with other acyl group. Accordingly, their process is poor in wide applicability.

N-(3-oxobutanoyl)-substituted NCAs, on the other hand, are reported in JP 48-86886 A. The substituent on the nitrogen atom is, however, limited only to an N-(3-oxobutanoyl) group introduced using a diketene in their production process, so that this process cannot introduce acyl groups which are widely used. Concerning the compounds represented by the formula (2) and the formula (3), respectively, no synthesis process is disclosed [M. Wakselman et al., Amino Acids, 7, 67-77 (1994); Reibel Leonard et al., Bull. Soc. Chim. Fr., 3, 1025-319 (1972)]. These articles disclose only the structures of such compounds, and therefore, no synthesis is feasible following the articles.

›BACKGROUND ART · 3 of 3

As described above, many of conventional reports are directed to alkyl- or urethane-substituted NCAs, and production and use of N-acyl-substituted NCAs are still considered to be very difficult or impossible although they are expected to have high utility [“Peptides, Proc. of the 5 th Europ. Symp., Oxford, September 1962”, Pergamon Press 1963, Compiled by G. T. Young, Pages 84-87; Yonezawa et al., “Yuki Gosei Kagaku (Synthetic Organic Chemistry)”, 47(9), 782-794 (1989)].

In short, N-acyl-substituted NCAs and various amino acid derivatives produced by amidation reactions making use of these NCAs are expected to find utility as useful compounds or production processes in many fields led by the fields of pharmaceuticals and agrochemicals. Nonetheless, neither commonly applicable production process of N-acyl-substituted NCAs nor widely applicable, industrially-excellent peptide production process making use of these NCAs were known practically to date.

›DISCLOSURE OF THE INVENTION

Objects of the present invention is to provide a novel amino acid N-carboxyanhydride with an N-acyl substituent on a nitrogen atom thereof, which is considered to be an important intermediate extremely useful in many fields led by the fields of pharmaceuticals and agrochemicals but cannot be obtained by the conventional production techniques, and its production process, and a production process of a diamide compound, which owing to use of the N-carboxyanhydride, does not develop problems such as racemization, includes fewer steps and is economical.

The present inventors have proceeded with an extensive investigation to achieve the above-described objects. As a result, they have succeeded in obtaining a novel amino acid N-carboxyanhydride with an N-acyl substituent on a nitrogen atom thereof and based on use of the compound, have also found a novel amidation reaction which does not develop problems such as racemization, leading to the completion of the present invention.

Described specifically, an amino acid N-carboxy-anhydride with a substituent on a nitrogen atom thereof according to the present invention has a structure represented by the following formula (1):

wherein R 1 and R 2 each independently represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heterocyclic alkyl group.

Examples of the invention compound represented by the formula (1) can include the following compounds:

1. Among compounds represented by the formula (1), those falling within neither the following category A nor the following category B:

A. Compounds of the formula (1) in which R 2 is a 2-oxopropyl group; and

B. Compounds of the following formulas (2) and (3):

2. Compounds of the formula (1) in which R 2 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted aralkyl group.

3. Compounds of the formula (1) in which R 2 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted aralkyl group, with a proviso that the compounds falling within the above category A or B are excluded.

4. Compounds of the formula (1) in which R 2 is a substituted or unsubstituted aryl group.

5. Compounds of the formula (1) in which R 2 is a substituted or unsubstituted aryl group, with a proviso that the compounds falling within the above category B are excluded.

6. Compounds of the formula (1) in which R 2 is a substituted or unsubstituted heterocycle or a substituted or unsubstituted heterocyclic alkyl group.

7. Compounds of the formula (1) in which R 1 is a side chain on an α-carbon atom of a protected or unprotected amino acid.

8. Compounds having any one of the structures described above under items 1-6, in which R 1 is a side chain on an α-carbon atom of a protected or unprotected amino acid.

A process according to the present invention for the production of the compound represented by the formula (1), in a first aspect thereof, comprises reacting, in an inert diluent and in the presence of a condensing agent, an amino acid N-carboxyanhydride represented by the following formula (4):

wherein R 1 has the same meaning as defined in claim 1 with a compound represented by the following formula (5):

wherein R 2 has the same meaning as defined in claim 1.

The process according to the present invention for the production of the compound represented by the formula (1), in a second aspect thereof, comprises reacting, in an inert diluent and in the presence of an amine base, an amino acid N-carboxyanhydride represented by the following formula (4):

wherein R 1 has the same meaning as defined in claim 1 with a compound represented by the following formula (6):

wherein R 2 has the same meaning as defined in claim 1 and Y represents a halogen atom.

A process according to the present invention for the production of an amide derivative represented by the following formula (8):

wherein R 1 and R 2 have the same meanings as defined above, and R 3 and R 4 each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heterocyclic alkyl group, which comprises a step of reacting a compound represented by the formula (1), for example, any one of the compounds exemplified above under items 1-8 with an amine derivative represented by the following formula (7):

wherein R 3 and R 4 have the same meanings as defined above.

The process according to the present invention for the production of the compound represented by the formula (8), in another aspect thereof, comprises a step of reacting a compound represented by the formula (1), for example, any one of the compounds exemplified above under items 1-8 with an unprotected or protected amino acid.

›BEST MODES FOR CARRYING OUT THE INVENTION · 1 of 2

The compounds according to the present invention will next be described in further detail.

The term “substituted or unsubstituted alkyl group” represented by R 1 , R 2 , R 3 and R 4 in the formulas (1), (4), (5), (6), (7) and (8) means an alkyl group which may be substituted at one or more desired parts thereof. Examples of the alkyl group can include methyl, ethyl, methoxyethyl, phenoxymethyl, benzyloxymethyl, methylthiomethyl, phenylthiomethyl, fluorenylmethyl, fluoroethyl, n-propyl, chloropropyl, isopropyl, n-butyl, (substituted amino)-n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.

The term “substituted or unsubstituted cycloalkyl group” means a cycloalkyl group which may be substituted at one or more desired parts thereof. Examples of the cycloalkyl group can include cyclopropyl, cyclobutyl, cyclopentyl, ethoxycyclopentyl, cyclohexyl, tert-butoxycyclohexyl, benzyloxycyclohexyl, nitrocyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.

The term “substituted or unsubstituted aralkyl group” means an aralkyl group which may be substituted at one or more desired parts thereof. Examples of the aralkyl group can include benzyl, 2-phenylethyl, 3-phenylpropyl, cinnamyl, naphthylmethyl, 3-chlorobenzyl, 4-aminobenzyl, 2-nitrobenzyl, 4-methoxybenzyl, 3,4-dihydroxybenzyl, and 3,4-dimethoxybenzyl.

The term “substituted or unsubstituted aryl group” means an aryl group which may be substituted at one or more desired parts thereof. Examples of the aryl group can include phenyl, tolyl, bromophenyl, methoxyphenyl, ethylphenyl, propylphenyl, nitrophenyl, amidophenyl, fluorenyl, naphthyl, hydroxynaphthyl, anthracenyl, phenanthrenyl, and benzophenanthrenyl.

The term “substituted or unsubstituted heterocycle” means a heterocycle which may be substituted at one or more desired parts thereof. Examples of the heterocycle can include tetrahydropyranyl, tetrahydrofuranyl, alkyltetrahydrofuranyl, tetrahydrothienyl, methylsulfonyltetrahydrothienyl, pyridyl, pyrazyl, pyrimidyl, thienyl, hydroxypyridyl, imidazolyl, thiazolyl, pyrazolyl, pyrazolonyl, isoxazolyl, isothiazyl, pyrrolyl, furanyl, naphthylidinyl, quinolyl, sulfamoylquinolyl, and sydononyl.

The term “substituted or unsubstituted heterocyclic alkyl group” means a heterocyclic alkyl group which may be substituted at one or more desired parts thereof. Examples of the heterocyclic alkyl group can include 3-pyridylmethyl, 4-pyridylmethyl, 6-methoxy-3-pyridylmethyl, 3-quinolylmethyl, N-methyl-4-imidazolemethyl, 2-amino-4-thiazolemethyl, and morpholinomethyl.

The term “side chain on an α-carbon atom of a protected or unprotected amino acid” means a side chain on an α-carbon atom of an amino acid such as alanine or valine, leucine, isoleucine, tert-leucine, serine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine, hydroxylysine, arginine, cysteine, cystine, methionine, phenylalanine, tyrosine, tryptophan, histidine, homoserine or ornithine, for example. Representative examples of the side chain can include those represented by the following formulas (9) to (29):

The above-described side chains may be protected with protecting groups by methods, both of which are known commonly to those having ordinary skill in the art, as desired. For example, they may be protected using a commonly-employed, amino-protecting group, thiol-protecting group or carboxy-protecting group.

Illustrative inert diluents, which are usable in the first and second aspects of the process according to the present invention for the production of the compound represented by the formula (1), are chlorine-containing organic solvents such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane and tetrachloroethane; esters such as methyl acetate, ethyl acetate and butyl acetate; ethers such as diethyl ether, diphenyl ether, dioxane and tetrahydrofuran; and hexane, liquid sulfur dioxide, carbon disulfide, benzene, toluene, xylene, nitromethane, nitrobenzene, acetonitrile, dimethylformamide, dimethylacetamide, and 1,3-dimethyl-2-imidazolidinone. They can be used either singly or in combination as needed.

Examples of the condensing agent can include thionyl chloride, thionyl bromide, N,N-dicyclohexylcarbodiimide, and 1,1-carbonyldiimidazole. They can be used either singly or in combination as needed.

Examples of the halogen atom represented by Y in the formula (6) can include a chlorine atom, bromine atom and iodine atom.

Illustrative of the amine base are trimethylamine, triethylamine, tributylamine, diisopropylethylamine, pyridine, lutidine, N,N-dimethylaniline, N,N-dimethyl-toluidine, 4-dimethylaminopyridine, N-methylmorpholine, diazabicycloundecene, and 1,8-bis(dimethylamino)-naphthalene.

Examples of the protected or unprotected amino acid usable as an amine in the production process of the compound of the formula (8) can include alanine, valine, leucine, isoleucine, tert-leucine, serine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine, hydroxylysine, arginine, cysteine, cystine, methionine, phenylalanine, tyrosine, tryptophan, histidine, homoserine, and ornithine. They can be used either singly or in combination as needed.

When the invention derivative represented by the formula (1) contains one or more asymmetric carbon atoms, the derivative may exist in the form of a specific stereoisomer or in the form of a mixture of stereoisomers including a racemic form.

Compounds encompassed by the formula (1) will be exemplified in Table 1 to Table 46, although they shall by no means restrict the compound according to the present invention. Incidentally, “Ph” in the tables means “a phenyl group” or “a phenylene group”.

The compound numbers described in the above tables correspond to the compound numbers to be described in Examples.

A description will hereinafter be made about certain representative production processes according to the present invention.

[Production process of an amino acid N-carboxyanhydride with a substituent on a nitrogen atom thereof, which is represented by the formula (1)]

›BEST MODES FOR CARRYING OUT THE INVENTION · 2 of 2

The compound represented by the formula (1) can be produced by reacting an amino acid N-carboxyanhydride, which is represented by the formula (4), with a compound of the formula (5) or (6).

Incidentally, the amino acid N-carboxyanhydride represented by the formula (4), which is used as a raw material in the production of the invention compound represented by the formula (1), can be produced by reacting the corresponding available amino acid with phosgene or by causing phosphorus trichloride, thionyl chloride or the like on an amino acid with a nitrogen atom thereof protected by urethane.

Further, the compound represented by the formula (5) or (6) is readily available from the market or by synthesis in a known manner.

The reaction temperature may range from −78 to 200° C., preferably from −50 to 50° C. The reaction time, on the other hand, may range from several minutes to 72 hours, preferably from several minutes to 24 hours.

[Production process of an amide derivative represented by the formula (8)]

The amidation reaction according to the present invention can be practiced by dissolving an N-substituted NCA in an inert diluent (for example, ethyl acetate) and then cooling the resulting solution under stirring. As an alternative, the reaction can be conducted in the absence of an inert diluent. Next, a solution of a desired amine (including a protected or unprotected amino acid) in an inert solvent (for example, ethyl acetate) is charged dropwise. This charging of the amine into a reaction system may also be conducted in the absence of an inert diluent. To the mixture so obtained, a base (for example, N-methylmorpholine, 4-dimethylaminopyridine or the like) is added. The base can promote a condensation reaction and can eliminate carbonic acid produced during the reaction, although it is not absolutely necessary to add the base.

Per mole of the N-substituted NCA, the desired amine may be used in an amount of from 1 to 20 equivalents, preferably from 1 to 5 equivalents, and the base, when to be added, may be used in an amount of from 0.1 to 20 equivalents, preferably from 0.1 to 5 equivalents.

When the inert diluent is used, the concentration of the N-substituted NCA may range from 0.01 to 50 mol/L, with a range of from 0.05 to 20 mol/L being preferred.

The reaction temperature may range from −78 to 200° C., preferably from −50 to 50° C. The reaction time, on the other hand, may range from several minutes to 72 hours, preferably from several minutes to 24 hours.

The amide derivative so completed can be purified by washing it with an aqueous acidic solution (for example, an aqueous solution of hydrochloric acid or an aqueous solution of potassium hydrogensulfate) to remove the unreacted amine, by washing it with an aqueous alkaline solution (for example, an aqueous solution of sodium hydroxide or an aqueous solution of sodium hydrogencarbonate) to eliminate byproducts formed by decomposition or the like, or by an operation such as recrystallization making use of an appropriate solvent. The amide derivative obtained by this purification is extremely uniform, and practically requires no further purification. As the concurrent formation of byproducts is very limited, the amide derivative is formed with extremely high yield and its purification is easy.

A description will next be described about racemization of an amino acid N-carboxyanhydride with a substituent of the acyl type on a nitrogen atom thereof as described herein. This compound can be readily converted into its corresponding diastereomer compound (diamide compound) by conducting a reaction with an optically active compound. It is possible to confirm racemization of the resulting diastereomer compound, because the surplus rate of the diastereomer can be easily determined by analyzing the compound, for example, by high-performance liquid chromatography, nuclear magnetic resonance spectroscopy or the like. The compounds and production processes described herein have been ascertained to be free of the problem of racemization because each of the compounds can be obtained in the form of a single diastereomer compound (diamide compound) alone by conducting the reaction under appropriate conditions.

Incidentally, the amine substituted by R 3 and R 4 , which is represented by the formula (7) and is used as a raw material in the production of the invention compound represented by the formula (8), is readily available from the market or by synthesis in a known manner.

›EXAMPLES

Examples and Referential Examples of the present invention will hereinafter be described. It should, however, be borne in mind that the present invention is by no means limited by them.

›Examples23
›Example 1

Synthesis of (S)-3-benzoyl-4-methyl-2,5-oxazolidinedione (L-N-benzoylalaline-NCA) (Compound No. 1017)

(S)-4-Methyl-2,5-oxazolidinedione (L-alanine-NCA) (230 mg, 2.0 mmol) was dissolved in ethyl acetate (23 mL), followed by the addition of benzoyl chloride (365 mg, 2.6 mmol) under ice cooling. Further, a solution of 4-dimethylaminopyridine (318 mg, 2.6 mmol) in ethyl acetate (11 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 3 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound as white crystals (351 mg, 80%).

Melting point: 104.2-105.1° C.(dec.)

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.74(3H, d, J=6.8 Hz), 5.13(1H, q, J=6.8 Hz), 7.44-7.54(2H, m), 7.61-7.65(1H, m), 7.72-7.75(2H, m).

IR(KBr)νmax 3379, 3074, 2991, 1865, 1822, 1698 cm −1

›Example 2

Synthesis of (S)-3-benzoyl-4-methyl-2,5-oxazolidinedione (L-N-benzoylalaline-NCA) (Compound No. 1017)

4-Dimethylaminopyridine (61 mg, 0.5 mmol) and N-methylmorpholine (152 mg, 1.5 mmol) were dissolved in ethyl acetate (15 mL), followed by the addition of (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (230 mg, 2.0 mmol) under ice cooling. Further, a solution of benzoyl chloride (281 mg, 2.0 mmol) in ethyl acetate (7 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound as white crystals (324 mg, 74%).

›Example 3

Synthesis of (S)-3-benzoyl-4-isopropyl-2,5-oxazolidinedione (L-N-benzoylvaline-NCA)

Benzoyl chloride (295 mg, 2.1 mmol) was dissolved in ethyl acetate (21 mL), followed by the addition of (S)-4-isopropyl-2,5-oxazolidinedione (L-valine-NCA) (286 mg, 2.0 mmol) under ice cooling. Further, a solution of 4-dimethylaminopyridine (257 mg, 2.1 mmol) in ethyl acetate (11 mL) was added dropwise under ice cooling over 20 minutes. The resulting mixture was allowed to rise as was in temperature from 09. After the mixture was stirred at room temperature for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound as white crystals (351 mg, 80%).

Melting point: 124.8-125.9° C. (dec.)

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.09(3H, d, J=6.8 Hz), 1.26(3H, d, J=7.1 Hz), 2.51(1H, m), 5.09(1H, d, J=3.7 Hz), 7.47-7.52(2H, m), 7.62-7.66(1H, m), 7.74-7.77(2H, m).

IR(KBr)νmax 2969, 2937, 2879, 1862, 1816, 1694 cm −1

›Example 4

Synthesis of (S)-3-benzoyl-4-tert-butyl-2,5-oxazolidinedione (L-N-benzoyl-tert-leucine-NCA) (Compound No. 9017)

In a similar manner as in Example 3, the title compound was obtained as white crystals (341 mg, 65%) by using benzoyl chloride (295 mg, 2.1 mmol), (S)-4-tert-butyl-2,5-oxazolidinedione (L-tert-leucine-NCA)(314 mg, 2.0 mmol), 4-dimethylaminopyridine (257 mg, 2.1 mmol) and ethyl acetate (32 mL).

Melting point: 127.8-128.9° C.(dec.)

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.15(9H, s), 5.10(1H, s), 7.52(2H, t, J=8.1 Hz), 7.67(1H, t, J=7.3 Hz), 7.86(2H, dd, J=1.2, 8.3 Hz).

IR(KBr)νmax 2983, 2963, 2876, 1860, 1808, 1704 cm −1

›Example 5

Synthesis of (S)-3-benzoyl-4-phenyl-2,5-oxazolidinedione (L-N-benzoylphenylalanine-NCA) (Compound No. 35017)

In a similar manner as in Example 3, the title compound was obtained as white crystals (476 mg, 81%) by using benzoyl chloride (295 mg, 2.1 mmol), (S)-4-phenyl-2,5-oxazolidinedione (L-phenylalanine-NCA)(382 mg, 2.0 mmol), 4-dimethylaminopyridine (257 mg, 2.1 mmol) and ethyl acetate (32 mL).

Melting point: 125.8-126.4° C. (dec.)

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 3.50(1H, d, J=2.9 Hz), 3.51(1H, d, J=5.6 Hz), 5.36(1H, dd, J=2.9, 5.6 Hz), 7.09-7.11(2H, m), 7.31-7.36(3H, m), 7.39-7.45(4H, m), 7.57-7.60(1H, m).

IR(KBr)νmax 3070, 3031, 1867, 1786, 1708 cm −1

›Example 6

Synthesis of (S)-3-benzoyl-4-benzyloxy-carbonylethyl-2,5-oxazolidinedione (L-N-benzoyl-O-benzylglutamic acid-NCA) (Compound No. 17017)

In a similar manner as in Example 3, the title compound was obtained as white crystals (573 mg, 78%) by using benzoyl chloride (295 mg, 2.1 mmol), (S)-4-benzyloxycarbonylethyl-2,5-oxazolidinedione (L-N-benzoyl-O-benzylglutamic acid-NCA)(527 mg, 2.0 mmol), 4-dimethylaminopyridine (257 mg, 2.1 mmol) and ethyl acetate (32 mL).

Melting point: 94.5-94.9° C. (dec.)

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 2.47-2.50(2H, m), 2.53-2.63(2H, m), 5.09(1H, d, J=12.0 Hz), 5.14(1H, d, J=12.2 Hz), 5.21(1H, t, J=5.5 Hz), 7.32-7.39(5H, m), 7.43-7.47(2H, m), 7.61(1H, t, J=7.6 Hz), 7.69(2H, dd, J=1.2, 8.1 Hz).

IR(KBr)νmax 3258, 3065, 2964, 1869, 1805, 1731, 1701 cm −1

›Example 7

Synthesis of (S)-3-(p-methylbenzoyl)-4-methyl-2,5-oxazolidinedione (L-N-(p-methylbenzoyl)-alanine-NCA) (Compound No. 1026)

p-Methylbenzoyl chloride (309 mg, 2.0 mmol) was dissolved in ethyl acetate (5 mL), followed by the addition of (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (230 mg, 2.0 mmol) under ice cooling. Further, a solution of 4-dimethylaminopyridine (244 mg, 2.0 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound (152 mg, 33%) as a colorless clear syrup.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.72(3H, d, J=7.1 Hz), 2.44(3H, s), 5.14(1H, q, J=7.1 Hz), 7.29(2H, d, J=8.1 Hz), 7.65(2H, d, J=8.3 Hz).

IR(KBr)νmax 3278, 2998, 2942, 1853, 1835, 1694 cm −1

›Example 8

Synthesis of (S)-3-(p-bromobenzoyl)-4-methyl-2,5-oxazolidinedione (L-N-(p-bromobenzoyl)-alanine-NCA) (Compound No. 1035)

In a similar manner as in Example 7, the title compound (238 mg, 40%) was obtained as a colorless clear syrup by using p-bromobenzoyl chloride (439 mg, 2.0 mmol), (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA)(230 mg, 2.0 mmol), 4-dimethylaminopyridine (244 mg, 2.0 mmol) and ethyl acetate (15 mL).

1 H-N.M .R.(CDCl 3 , 400 MHz) δ 1.74(3H, d, J=6.8 Hz), 5.13(1H, q, J=6.8 Hz), 7.61(2H, d, J=2.3 Hz), 7.63(2H, d, J=2.3 Hz).

IR(KBr)νmax 3350, 2998, 2942, 1855, 1840, 1698 cm −1

›Example 9

Synthesis of (S)-3-acetyl-4-methyl-2,5-oxazolidinedione (L-N-acetylalanine-NCA) (Compound No. 1001)

(S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of acetyl chloride (306 mg, 3.9 mmol) under ice cooling. Further, a solution of N-methyl-morpholine (394 mg, 3.9 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in chloroform (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound (350 mg, 74%) as a colorless clear syrup.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.69(3H, d, J=6.9 Hz), 2.59(3H, s), 4.80(1H, q, J=6.9 Hz).

IR(neat)νmax 3405, 2945, 1864, 1794, 1720 cm −1

›Example 10

Synthesis of (S)-3-acetyl-4-methyl-2,5-oxazolidinedione (L-N-acetylalanine-NCA) (Compound No. 1001)

(S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of acetyl chloride (306 mg, 3.9 mmol) under ice cooling. Further, a solution of 4-dimethyl-aminopyridine (476 mg, 3.9 mmol) in ethyl acetate (15 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in ethyl acetate (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound (118 mg, 25%) as a colorless clear syrup.

›Example 11

Synthesis of (S)-3-decanoyl-4-methyl-2,5-oxazolidinedione (L-N-decanoylalanine-NCA) (Compound No. 1013)

(S)-4-methyl-2, 5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of decanoyl chloride (744 mg, 3.9 mmol) under ice cooling. Further, a solution of N-methylmorpholine (394 mg, 3.9 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes, and the resulting mixture was then stirred at the same temperature for 2 hours, the reaction mixture was treated in a similar manner as in Synthesis Process 5 of Example 8 to afford the title compound (525 mg, 65%) as a colorless clear syrup. A portion of the thus-obtained syrup was recrystallized from hexane to obtain white crystals (280 mg).

Melting point: 61-63° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 0.88(3H, t, J=6.9 Hz), 1.27(12H, bs), 1.68(3H, d, J=7.3 Hz), 1.73-1.60(2H, m), 2.93(2H, t, J=7.6 Hz), 4.81(1H, q, J=7.3 Hz).

IR(KBr)νmax 2926, 2857, 1868, 1801, 1715 cm −1

›Example 12

Synthesis of (S)-3-(3-phenylpropanoyl)-4-methyl-2,5-oxazolidinedione (L-N-(3-phenylpropanoyl)-alanine-NCA) (Compound No. 1019)

(S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of 3-phenylpropanoyl chloride (658 mg, 3.9 mmol) under ice cooling. Further, a solution of N-methyl-morpholine (394 mg, 3.9 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes, and the resulting mixture was then stirred at the same temperature for 2 hours. The reaction mixture was treated in a similar manner as in Synthesis Process 5 of Example 8 to afford the title compound (408 mg, 55%) as a colorless clear syrup.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.64(3H, d, J=6.8 Hz), 3.03-2.99(2H, m), 3.29-3.19(2H, m), 4.78(1H, q, J=6.8 Hz), 7.32-7.18(5H, m).

IR(neat)νmax 3405, 2910, 2850, 1860, 1803, 1720 cm −1

›Example 13

Synthesis of N-benzoyl-L-alanyl-L-phenylalanine methyl ester (Compound No. 30)

L-Phenylalanine methyl ester hydrochloride (518 mg, 2.4 mmol) was suspended in tetrahydrofuran (12 mL), and at 0° C., N-methylmorpholine (242 mg, 2.4 mmol) was added, followed by stirring for 20 minutes. (S)-3-Benzoyl-4-methyl-2,5-oxazolidinedione (N-benzoyl-L-alanine-NCA (438 mg, 2 mmol) was added as crystals at 0° C. After the resulting mixture was stirred for 15 minutes, the mixture was allowed to rise in temperature to room temperature, at which the mixture was stirred for 15 minutes. The reaction mixture was poured into 1 N hydrochloric acid (25 mL), followed by extraction with ethyl acetate (25 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (25 mL) and a saturated aqueous solution of sodium chloride (25 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure. The resulting white solid was washed with hexane-ethyl acetate to afford the title compound (462 mg, 65%) as white crystals.

Melting point: 134-135° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.45(3H, d, J=7.0 Hz), 3.05(1H, dd, J=13.9, 6.8 Hz), 3.16(1H, dd, J=13.9, 5.6 Hz), 3.74(3H, s,), 4.71(1H, quintet, J=7.0 Hz), 4.88-4.85(1H, m), 6.78-6.74(2H, m), 7.16-7.06(5H, m), 7.53-7.42(3H, m), 7.77(2H, d, J=7.0 Hz).

IR(KBr)νmax 3298, 3062, 3025, 2976, 2932, 1741, 1661, 1630, 1536, 1451 cm −1

›Example 14

Synthesis of N-benzoyl-L-alanine-(S)-1-(p-tolyl)ethylamide (Compound No. 31)

(S)-3-Benzoyl-4-methyl-2,5-oxazolidinedione (N-benzoyl-L-alanine-NCA) (110 mg, 0.50 mmol) was dissolved in ethyl acetate (2.5 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (68 mg, 0.50 mmol) in ethyl acetate (2.5 mL) at 0° C. A solution of N-methylmorpholine (61 mg, 0.6 mmol) in ethyl acetate (3.0 mL) was then added, followed by stirring for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (149 mg, 97%) as white crystals.

Melting point: 158.6-160.1° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.46(3H, d, J=7.2 Hz), 1.48(3H, d, J=6.8 Hz), 2.33(3H, s), 4.80 (1H, quintet, J=7.1 Hz), 5.06(1H, quintet, J=7.1 Hz), 7.15(2H, d, J=8.1 Hz), 7.25(2H, d, J=8.1 Hz), 7.40-7.43(1H, m), 7.43(2H, d, J=7.6 Hz), 7.79(2H, d, J=7.6 Hz).

IR(KBr)νmax 3308, 2978, 2935, 1660, 1639, 1603, 1580, 1527, 1490 cm −1

›Example 15

Synthesis of N-benzoyl-L-valine-(S)-1-(p-tolyl)ethylamide (Compound No. 32)

(S)-3-Benzoyl-4-isopropyl-2,5-oxazolidinedione (N-benzoyl-L-valine-NCA) (100 mg, 0.40 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (55 mg, 0.40 mmol) and N-methylmorpholine (61 mg, 0.60 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (134 mg, 98%) as white crystals.

Melting point: 214.4-215.3° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 0.95(3H, d, J=6.6 Hz), 0.96(3H, d, J=6.8 Hz), 1.42(3H, d, J=6.8 Hz), 2.13-2.21(1H, m), 2.33(3H, s), 4.53(1H, dd, J=8.5, 7.3 Hz), 5.06(1H, quintet, J=7.3 Hz), 6.70(1H, brd, J=7.8 Hz), 6.98(1H, brd, J=8.8 Hz), 7.14(2H, d, J=7.8 Hz), 7.21(2H, d, J=8.3 Hz), 7.41(2H, t, J=8.1 Hz), 7.50(1H, t, J=7.5 Hz), 7.79(2H, dd, J=8.1, 1.5 Hz).

IR(KBr)νmax 3284, 3059, 2970, 2927, 2871, 1654, 1633, 1579, 1541, 1490 cm −1

›Example 16

Synthesis of N-benzoyl-L-tert-leucine-(S)-1-(p-tolyl)ethylamide (Compound No. 33)

(S)-3-Benzoyl-4-tert-butyl-2,5-oxazolidinedione (N-benzoyl-L-tert-leucine-NCA)(100 mg, 0.38 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (52 mg, 0.38 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (66 mg, 49%) as white crystals.

Melting point: 144.0-144.8° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.00(9H, s), 1.43(3H, d, J=6.8 Hz), 2.34(3H, s), 4.51(1H, d, J=9.3 Hz), 5.07(1H, quintet, J=7.3 Hz), 6.38(1H, brd, J=7.6 Hz), 6.96(1H, brd, J=7.0 Hz), 7.14(2H, d, J=7.8 Hz), 7.21(2H, d, J=8.1 Hz), 7.43(2H, t, J=7.8 Hz), 7.51(1H, t, J=7.3 Hz), 7.79(2H, dd, J=8.3, 1.2 Hz).

IR(KBr)νmax 3274, 3065, 2968, 2872, 1636, 1579, 1525 cm −1

›Example 17

Synthesis of N-benzoyl-L-phenylalanine-(S)-1-(p-tolyl)ethylamide (Compound No. 34)

(S)-3-Benzoyl-benzoyl-2,5-oxazolidinedione (N-benzoyl-L-phenylalanine-NCA)(100 mg, 0.34 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (46 mg, 0.34 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (110 mg, 84%) as white crystals.

Melting point: 214.2-214.9° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.38(3H, d, J=7.1 Hz), 2.34(3H, s,), 3.05(1H, dd, J=13.4, 8.5 Hz), 3.20(1H, dd, J=13.4, 5.6 Hz), 4.82(1H, dt, J=8.3, 5.6 Hz), 4.99(1H, quintet, J=7.2 Hz), 6.03(1H, brd, J=7.8 Hz), 6.96(1H, brd, J=5.9 Hz), 6.98(1H, d, J=8.1 Hz), 7.09(1H, d, J=7.8 Hz), 7.14-7.17(1H, m), 7.18(4H, m), 7.42(2H, dt, J=7.8, 1.2 Hz), 7.50(1H, t, J=7.3 Hz), 7.74(2H, dd, J=8.3, 1.2 Hz).

IR(KBr)νmax 3289, 3063, 3030, 2974, 2926, 1653, 1632, 1604, 1579, 1541 cm −1

›Example 18

Synthesis of N-benzoyl-O-benzyl-L-glutamic acid-(S)-1-(p-tolyl)ethylamide (Compound No. 35)

(S)-3-Benzoyl-4-benzyloxycarbonylethyl-2,5-oxazolidinedione (L-N-benzoyl-O-benzylglutamic acid-NCA)(100 mg, 0.27 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (37 mg, 0.27 mmol) and N-methylmorpholine (28 mg, 0.27 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (106 mg, 85%) as white crystals.

Melting point: 123.4-124.9° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.43(3H, d, J=7.1 Hz), 2.04-2.23(2H, m), 2.32(3H, s), 2.34-2.67(2H, m), 4.69-4.74(1H, m), 5.00-5.07(1H, m), 5.10(2H, s), 6.85-6.94(1H, m), 7.12(2H, d, J=8.2 Hz), 7.19(2H, d, J=8.2 Hz), 7.29-7.36(6H, m), 7.40-7.45(2H, m), 7.49-7.52(1H, m), 7.80(2H, dd, J=8.3, 1.2 Hz).

IR(KBr)νmax 3289, 3060, 3032, 2974, 2931, 1726, 1630, 1579, 1534 cm −1

›Example 19

Synthesis of N-acetyl-L-alanine-(S)-1-(p-tolyl)ethylamide (Compound No. 36)

(S)-3-Acetyl-4-methyl-2,5-oxazolidinedione (N-acetyl-L-alanine-NCA)(424 mg, 2.7 mmol) was dissolved in ethyl acetate (10 mL), followed by the addition of (S)-1-(p-tolyl)ethylamine (406 mg, 3 mmol) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (25 mL), followed by extraction with ethyl acetate (25 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (25 mL) and a saturated aqueous solution of sodium chloride (25 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure, and the resulting white solid was washed with hexane-ethyl acetate to afford the title compound (380 mg, 57%) as white crystals.

Melting point: 201-203° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 1.32(3H, d, J=7.9 Hz), 1.44(3H, d, J=7.9 Hz), 1.98(3H, s), 2.32(3H, s), 4.54(1H, quintet, J=7.9 Hz), 5.01(1H, quintet, J=7.9 Hz), 6.48(1H, brd, J=7.9 Hz), 6.88(1H, brd, J=7.9 Hz), 7.20-7.10(4H, m).

IR(KBr)νmax 3292, 1633, 1546, 1444 cm −1

›Example 20

Synthesis of N-decanoyl-L-alanyl-L-phenylalanine methyl ester (Compound No. 37)

L-Phenylalanine methyl ester hydrochloride (259 mg, 1.2 mmol) was suspended in tetrahydrofuran (6 mL), followed by the addition of N-methylmorpholine (121 mg, 1.2 mmol) at 0° C. The resulting mixture was stirred for 20 minutes. (S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (270 mg, 1 mmol) was added as crystals at 0° C., followed by stirring for 5 minutes. The mixture was allowed to rise in temperature to room temperature, at which the mixture was stirred for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (289 mg, 71%) as white crystals.

Melting point: 120-122° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 0.88(3H, t, J=6.8 Hz), 1.30-1.25(12H, m), 1.32(3H, d, J=7.1 Hz), 1.61-1.58(2H, m), 2.15(2H, t, J=7.8 Hz), 3.06(1H, dd, J=6.6, 13.9 Hz), 3.14(1H, dd, J=5.6, 13.9 Hz), 3.72(3H, s), 4.50-4.44(1H, m), 4.85-4.80(1H, m), 6.00(1H, brd, J=7.8 Hz), 6.57(1H, brd, J=7.8 Hz), 7.11-7.09(2H, m), 7.30-7.23(3H, m).

IR(KBr)νmax 3298, 3061, 2923, 2852, 1750, 1644, 1541, 1453 cm −1

›Example 21

Synthesis of N-decanoyl-L-alanine-(S)-1-(p-tolyl)ethylamide (Compound No. 38)

(S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (100 mg, 0.37 mmol) was dissolved in tetrahydrofuran (3 mL), and at 0° C., (S)-1-(p-tolyl)ethylamine (49 mg, 0.36 mmol) and N-methylmorpholine (37 mg, 0.36 mmol) were added, followed by stirring for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (103 mg, 77%) as white crystals.

Melting point: 153-154° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 0.88(3H, t, J=6.8 Hz), 1.33-1.20(12H, m), 1.33(3H, d, J=6.8 Hz), 1.44(3H, d, J=6.8 Hz), 1.71-1.59(2H, m), 2.18(2H, t, J=7.2 Hz), 2.33(3H, s), 4.53(1H, quintet, J=6.8 Hz), 5.02(1H, quintet, J=6.8 Hz), 6.28(1H, brs), 6.84(1H, brs), 7.13(2H, d, J=8.1 Hz), 7.20(2H, d, J=8.1 Hz).

IR(KBr)νmax 3297, 2920, 2852, 1638, 1556, 1452 cm −1

›Example 22

Synthesis of N-decanoyl-L-alaninebutylamide (Compound No. 39)

(S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (270 mg, 1 mmol) was dissolved in tetrahydrofuran (6 mL), and at 0° C., butylamine (146 mg, 2 mmol) was added, followed by stirring for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (217 mg, 73%) as white crystals.

Melting point: 128-130° C.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 0.88(3H, t, J=6.8 Hz), 0.92(3H, t, J=7.3 Hz), 1.36-1.26(14H, m), 1.36(3H, d, J=7.6 Hz), 1.52-1.45(2H, m), 1.63-1.57(2H, m), 2.23-2.15(2H, m), 3.27-3.21(2H, m), 4.51(1H, quintet, J=7.6 Hz), 6.34(1H, brd, J=7.6 Hz), 6.61(1H, brs).

IR(KBr)νmax 3295, 3096, 2959, 2925, 2853, 1634, 1545, 1468 cm −1

›Example 23

Synthesis of N-decanoyl-L-alaninemorpholino-amide (Compound No. 40)

(S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (100 mg, 0.37 mmol) was dissolved in tetrahydrofuran (3 mL), and at 0° C., morpholine (52 mg, 0.6 mmol) was added, followed by stirring for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (112 mg, 97%) as a colorless clear syrup.

1 H-N.M.R.(CDCl 3 , 400 MHz) δ 0.88(3H, t, J=6.9 Hz), 1.32-1.19(12H, m), 1.31(3H, d, J=7.8 Hz), 1.64-1.59(2H, m), 2.20(2H, t, J=7.6 Hz), 3.61-3.47(4H, m), 3.73-3.66(4H, m), 4.89(1H, quintet, J=7.8 Hz), 6.60-6.55(1H, m).

IR(neat)νmax 3308, 2926, 2856, 1637, 1535, 1466 cm −1

›INDUSTRIAL APPLICABILITY

The invention compounds represented by the formula (1) readily react with nucleophilic reagents such as free amines, and use of these compounds permits high-yield, mass and low-cost production of amino acid derivatives, optically active compounds, peptides, polypeptides or the like without racemization. The novel compounds and novel production processes according to the present invention, therefore, are extremely useful and are expected to find themselves as industrially-excellent compounds and processes in many fields led by the fields of pharmaceuticals and agrochemicals.

›Tables in the description — 46
TABLE 1
Compound No.R2Compound No.R2
1001CH31045
1002CH2CH31046
1003(CH2)2CH31047
1004CH(CH3)21048
1005(CH2)3CH31049
1006CH2CH(CH3)21050
1007CH(CH3)CH2CH31051
1008C(CH3)31052
1009(CH2)4CH31053
1010(CH2)5CH31054
1011(CH2)6CH31055
1012(CH2)7CH31056
1013(CH2)8CH31057
1014cyclopropyl1058
1015cyclobutyl1059
1016cyclohexyl1060
1017Ph1061
1018PhCH21062
1019Ph(CH2)2
1020Ph(CH2)3
1021PhO(CH2)2
1022PhCH2OCH2CH2
1023PhCH2O(C═O)CH2CH2
1024o-CH3Ph
1025m-CH3Ph
1026p-CH3Ph
10272,4-(CH3)2Ph
10283,5-(CH3)2Ph
10292,4,6-(CH3)3Ph
1030p-CH3OPh
1031p-CH3CH2OPh
1032p-CH3(CH2)2OPh
1033p-FPh
1034p-ClPh
1035p-BrPh
1036p-IPh
1037p-PhOPh
1038p-PhCH2OPh
1039p-NO2Ph
1040p-CNPh
1041p-CH3SO2Ph
1042
1043
1044
TABLE 2
Compound No.R2Compound No.R2
2001CH32045
2002CH2CH32046
2003(CH2)2CH32047
2004CH(CH3)22048
2005(CH2)3CH32049
2006CH2CH(CH3)22050
2007CH(CH3)CH2CH32051
2008C(CH3)32052
2009(CH2)4CH32053
2010(CH2)5CH32054
2011(CH2)6CH32055
2012(CH2)7CH32056
2013(CH2)8CH32057
2014cyclopropyl2058
2015cyclobutyl2059
2016cyclohexyl2060
2017Ph2061
2018PhCH22062
2019Ph(CH2)2
2020Ph(CH2)3
2021PhO(CH2)2
2022PhCH2OCH2CH2
2023PhCH2O(C═O)CH2CH2
2024o-CH3Ph
2025m-CH3Ph
2026p-CH3Ph
20272,4-(CH3)2Ph
20283,5-(CH3)2Ph
20292,4,6-(CH3)3Ph
2030p-CH3OPh
2031p-CH3CH2OPh
2032p-CH3(CH2)2OPh
2033p-FPh
2034p-ClPh
2035p-BrPh
2036p-IPh
2037p-PhOPh
2038p-PhCH2OPh
2039p-NO2Ph
2040p-CNPh
2041p-CH3SO2Ph
2042
2043
2044
TABLE 3
Compound No.R2Compound No.R2
3001CH33045
3002CH2CH33046
3003(CH2)2CH33047
3004CH(CH3)23048
3005(CH2)3CH33049
3006CH2CH(CH3)23050
3007CH(CH3)CH2CH33051
3008C(CH3)33052
3009(CH2)4CH33053
3010(CH2)5CH33054
3011(CH2)6CH33055
3012(CH2)7CH33056
3013(CH2)8CH33057
3014cyclopropyl3058
3015cyclobutyl3059
3016cyclohexyl3060
3017Ph3061
3018PhCH23062
3019Ph(CH2)2
3020Ph(CH2)3
3021PhO(CH2)2
3022PhCH2OCH2CH2
3023PhCH2O(C═O)CH2CH2
3024o-CH3Ph
3025m-CH3Ph
3026p-CH3Ph
30272,4-(CH3)2Ph
30283,5-(CH3)2Ph
30292,4,6-(CH3)3Ph
3030p-CH3OPh
3031p-CH3CH2OPh
3032p-CH3(CH2)2OPh
3033p-FPh
3034p-ClPh
3035p-BrPh
3036p-IPh
3037p-PhOPh
3038p-PhCH2OPh
3039p-NO2Ph
3040p-CNPh
3041p-CH3SO2Ph
3042
3043
3044
TABLE 4
Compound No.R2Compound No.R2
4001CH34045
4002CH2CH34046
4003(CH2)2CH34047
4004CH(CH3)24048
4005(CH2)3CH34049
4006CH2CH(CH3)24050
4007CH(CH3)CH2CH34051
4008C(CH3)34052
4009(CH2)4CH34053
4010(CH2)5CH34054
4011(CH2)6CH34055
4012(CH2)7CH34056
4013(CH2)8CH34057
4014cyclopropyl4058
4015cyclobutyl4059
4016cyclohexyl4060
4017Ph4061
4018PhCH24062
4019Ph(CH2)2
4020Ph(CH2)3
4021PhO(CH2)2
4022PhCH2OCH2CH2
4023PhCH2O(C═O)CH2CH2
4024o-CH3Ph
4025m-CH3Ph
4026p-CH3Ph
40272,4-(CH3)2Ph
40283,5-(CH3)2Ph
40292,4,6-(CH3)3Ph
4030p-CH3OPh
4031p-CH3CH2OPh
4032p-CH3(CH2)2OPh
4033p-FPh
4034p-ClPh
4035p-BrPh
4036p-IPh
4037p-PhOPh
4038p-PhCH2OPh
4039p-NO2Ph
4040p-CNPh
4041p-CH3SO2Ph
4042
4043
4044
TABLE 5
Compound No.R2Compound No.R2
5001CH35045
5002CH2CH35046
5003(CH2)2CH35047
5004CH(CH3)25048
5005(CH2)3CH35049
5006CH2CH(CH3)25050
5007CH(CH3)CH2CH35051
5008C(CH3)35052
5009(CH2)4CH35053
5010(CH2)5CH35054
5011(CH2)6CH35055
5012(CH2)7CH35056
5013(CH2)8CH35057
5014cyclopropyl5058
5015cyclobutyl5059
5016cyclohexyl5060
5017Ph5061
5018PhCH25062
5019Ph(CH2)2
5020Ph(CH2)3
5021PhO(CH2)2
5022PhCH2OCH2CH2
5023PhCH2O(C═O)CH2CH2
5024o-CH3Ph
5025m-CH3Ph
5026p-CH3Ph
50272,4-(CH3)2Ph
50283,5-(CH3)2Ph
50292,4,6-(CH3)3Ph
5030p-CH3OPh
5031p-CH3CH2OPh
5032p-CH3(CH2)2OPh
5033p-FPh
5034p-ClPh
5035p-BrPh
5036p-IPh
5037p-PhOPh
5038p-PhCH2OPh
5039p-NO2Ph
5040p-CNPh
5041p-CH3SO2Ph
5042
5043
5044
TABLE 6
Compound No.R2Compound No.R2
6001CH36045
6002CH2CH36046
6003(CH2)2CH36047
6004CH(CH3)26048
6005(CH2)3CH36049
6006CH2CH(CH3)26050
6007CH(CH3)CH2CH36051
6008C(CH3)36052
6009(CH2)4CH36053
6010(CH2)5CH36054
6011(CH2)6CH36055
6012(CH2)7CH36056
6013(CH2)8CH36057
6014cyclopropyl6058
6015cyclobutyl6059
6016cyclohexyl6060
6017Ph6061
6018PhCH26062
6019Ph(CH2)2
6020Ph(CH2)3
6021PhO(CH2)2
6022PhCH2OCH2CH2
6023PhCH2O(C═O)CH2CH2
6024o-CH3Ph
6025m-CH3Ph
6026p-CH3Ph
60272,4-(CH3)2Ph
60283,5-(CH3)2Ph
60292,4,6-(CH3)3Ph
6030p-CH3OPh
6031p-CH3CH2OPh
6032p-CH3(CH2)2OPh
6033p-FPh
6034p-ClPh
6035p-BrPh
6036p-IPh
6037p-PhOPh
6038p-PhCH2OPh
6039p-NO2Ph
6040p-CNPh
6041p-CH3SO2Ph
6042
6043
6044
TABLE 7
Compound No.R2Compound No.R2
7001CH37045
7002CH2CH37046
7003(CH2)2CH37047
7004CH(CH3)27048
7005(CH2)3CH37049
7006CH2CH(CH3)27050
7007CH(CH3)CH2CH37051
7008C(CH3)37052
7009(CH2)4CH37053
7010(CH2)5CH37054
7011(CH2)6CH37055
7012(CH2)7CH37056
7013(CH2)8CH37057
7014cyclopropyl7058
7015cyclobutyl7059
7016cyclohexyl7060
7017Ph7061
7018PhCH27062
7019Ph(CH2)2
7020Ph(CH2)3
7021PhO(CH2)2
7022PhCH2OCH2CH2
7023PhCH2O(C═O)CH2CH2
7024o-CH3Ph
7025m-CH3Ph
7026p-CH3Ph
70272,4-(CH3)2Ph
70283,5-(CH3)2Ph
70292,4,6-(CH3)3Ph
7030p-CH3OPh
7031p-CH3CH2OPh
7032p-CH3(CH2)2OPh
7033p-FPh
7034p-ClPh
7035p-BrPh
7036p-IPh
7037p-PhOPh
7038p-PhCH2OPh
7039p-NO2Ph
7040p-CNPh
7041p-CH3SO2Ph
7042
7043
7044
TABLE 8
Compound No.R2Compound No.R2
8001CH38045
8002CH2CH38046
8003(CH2)2CH38047
8004CH(CH3)28048
8005(CH2)3CH38049
8006CH2CH(CH3)28050
8007CH(CH3)CH2CH38051
8008C(CH3)38052
8009(CH2)4CH38053
8010(CH2)5CH38054
8011(CH2)6CH38055
8012(CH2)7CH38056
8013(CH2)8CH38057
8014cyclopropyl8058
8015cyclobutyl8059
8016cyclohexyl8060
8017Ph8061
8018PhCH28062
8019Ph(CH2)2
8020Ph(CH2)3
8021PhO(CH2)2
8022PhCH2OCH2CH2
8023PhCH2O(C═O)CH2CH2
8024o-CH3Ph
8025m-CH3Ph
8026p-CH3Ph
80272,4-(CH3)2Ph
80283,5-(CH3)2Ph
80292,4,6-(CH3)3Ph
8030p-CH3OPh
8031p-CH3CH2OPh
8032p-CH3(CH2)2OPh
8033p-FPh
8034p-ClPh
8035p-BrPh
8036p-IPh
8037p-PhOPh
8038p-PhCH2OPh
8039p-NO2Ph
8040p-CNPh
8041p-CH3SO2Ph
8042
8043
8044
TABLE 9
Compound No.R2Compound No.R2
9001CH39045
9002CH2CH39046
9003(CH2)2CH39047
9004CH(CH3)29048
9005(CH2)3CH39049
9006CH2CH(CH3)29050
9007CH(CH3)CH2CH39051
9008C(CH3)39052
9009(CH2)4CH39053
9010(CH2)5CH39054
9011(CH2)6CH39055
9012(CH2)7CH39056
9013(CH2)8CH39057
9014cyclopropyl9058
9015cyclobutyl9059
9016cyclohexyl9060
9017Ph9061
9018PhCH29062
9019Ph(CH2)2
9020Ph(CH2)3
9021PhO(CH2)2
9022PhCH2OCH2CH2
9023PhCH2O(C═O)CH2CH2
9024o-CH3Ph
9025m-CH3Ph
9026p-CH3Ph
90272,4-(CH3)2Ph
90283,5-(CH3)2Ph
90292,4,6-(CH3)3Ph
9030p-CH3OPh
9031p-CH3CH2OPh
9032p-CH3(CH2)2OPh
9033p-FPh
9034p-ClPh
9035p-BrPh
9036p-IPh
9037p-PhOPh
9038p-PhCH2OPh
9039p-NO2Ph
9040p-CNPh
9041p-CH3SO2Ph
9042
9043
9044
TABLE 10
Compound No.R2Compound No.R2
10001CH310045
10002CH2CH310046
10003(CH2)2CH310047
10004CH(CH3)210048
10005(CH2)3CH310049
10006CH2CH(CH3)210050
10007CH(CH3)CH2CH310051
10008C(CH3)310052
10009(CH2)4CH310053
10010(CH2)5CH310054
10011(CH2)6CH310055
10012(CH2)7CH310056
10013(CH2)8CH310057
10014cyclopropyl10058
10015cyclobutyl10059
10016cyclohexyl10060
10017Ph10061
10018PhCH210062
10019Ph(CH2)2
10020Ph(CH2)3
10021PhO(CH2)2
10022PhCH2OCH2CH2
10023PhCH2O(C═O)CH2CH2
10024o-CH3Ph
10025m-CH3Ph
10026p-CH3Ph
100272,4-(CH3)2Ph
100283,5-(CH3)2Ph
100292,4,6-(CH3)3Ph
10030p-CH3OPh
10031p-CH3CH2OPh
10032p-CH3(CH2)2OPh
10033p-FPh
10034p-ClPh
10035p-BrPh
10036p-IPh
10037p-PhOPh
10038p-PhCH2OPh
10039p-NO2Ph
10040p-CNPh
10041p-CH3SO2Ph
10042
10043
10044
TABLE 11
Compound No.R2
11001CH3
11002CH2CH3
11003(CH2)2CH3
11004CH(CH3)2
11005(CH2)3CH3
11006CH2CH(CH3)2
11007CH(CH3)CH2CH3
11008C(CH3)3
11009(CH2)4CH3
11010(CH2)5CH3
11011(CH2)6CH3
11012(CH2)7CH3
11013(CH2)8CH3
11014cyclopropyl
11015cyclobutyl
11016cyclohexyl
11017Ph
11018PhCH2
11019Ph(CH2)2
11020Ph(CH2)3
11021PhO(CH2)2
11022PhCH2OCH2CH2
11023PhCH2O(C═O)CH2CH2
11024o-CH3Ph
11025m-CH3Ph
11026p-CH3Ph
110272,4-(CH3)2Ph
110283,5-(CH3)2Ph
110292,4,6-(CH3)3Ph
11030p-CH3OPh
11031p-CH3CH2OPh
11032p-CH3(CH2)2OPh
11033p-FPh
11034p-ClPh
11035p-BrPh
11036p-IPh
11037p-PhOPh
11038p-PhCH2OPh
11039p-NO2Ph
11040p-CNPh
11041p-CH3SO2Ph
11042
11043
11044
11045
11046
11047
11048
11049
11050
11051
11052
11053
11054
11055
11056
11057
11058
11059
11060
11061
11062
TABLE 12
Compound No.R2
12001CH3
12002CH2CH3
12003(CH2)2CH3
12004CH(CH3)2
12005(CH2)3CH3
12006CH2CH(CH3)2
12007CH(CH3)CH2CH3
12008C(CH3)3
12009(CH2)4CH3
12010(CH2)5CH3
12011(CH2)6CH3
12012(CH2)7CH3
12013(CH2)8CH3
12014cyclopropyl
12015cyclobutyl
12016cyclohexyl
12017Ph
12018PhCH2
12019Ph(CH2)2
12020Ph(CH2)3
12021PhO(CH2)2
12022PhCH2OCH2CH2
12023PhCH2O(C═O)CH2CH2
12024o-CH3Ph
12025m-CH3Ph
12026p-CH3Ph
120272,4-(CH3)2Ph
120283,5-(CH3)2Ph
120292,4,6-(CH3)3Ph
12030p-CH3OPh
12031p-CH3CH2OPh
12032p-CH3(CH2)2OPh
12033p-FPh
12034p-ClPh
12035p-BrPh
12036p-IPh
12037p-PhOPh
12038p-PhCH2OPh
12039p-NO2Ph
12040p-CNPh
12041p-CH3SO2Ph
12042
12043
12044
12045
12046
12047
12048
12049
12050
12051
12052
12053
12054
12055
12056
12057
12058
12059
12060
12061
12062
TABLE 13
Compound No.R2
13001CH3
13002CH2CH3
13003(CH2)2CH3
13004CH(CH3)2
13005(CH2)3CH3
13006CH2CH(CH3)2
13007CH(CH3)CH2CH3
13008C(CH3)3
13009(CH2)4CH3
13010(CH2)5CH3
13011(CH2)6CH3
13012(CH2)7CH3
13013(CH2)8CH3
13014cyclopropyl
13015cyclobutyl
13016cyclohexyl
13017Ph
13018PhCH2
13019Ph(CH2)2
13020Ph(CH2)3
13021PhO(CH2)2
13022PhCH2OCH2CH2
13023PhCH2O(C═O)CH2CH2
13024o-CH3Ph
13025m-CH3Ph
13026p-CH3Ph
130272,4-(CH3)2Ph
130283,5-(CH3)2Ph
130292,4,6-(CH3)3Ph
13030p-CH3OPh
13031p-CH3CH2OPh
13032p-CH3(CH2)2OPh
13033p-FPh
13034p-ClPh
13035p-BrPh
13036p-IPh
13037p-PhOPh
13038p-PhCH2OPh
13039p-NO2Ph
13040p-CNPh
13041p-CH3SO2Ph
13042
13043
13044
13045
13046
13047
13048
13049
13050
13051
13052
13053
13054
13055
13056
13057
13058
13059
13060
13061
13062
TABLE 14
Compound No.R2
14001CH3
14002CH2CH3
14003(CH2)2CH3
14004CH(CH3)2
14005(CH2)3CH3
14006CH2CH(CH3)2
14007CH(CH3)CH2CH3
14008C(CH3)3
14009(CH2)4CH3
14010(CH2)5CH3
14011(CH2)6CH3
14012(CH2)7CH3
14013(CH2)8CH3
14014cyclopropyl
14015cyclobutyl
14016cyclohexyl
14017Ph
14018PhCH2
14019Ph(CH2)2
14020Ph(CH2)3
14021PhO(CH2)2
14022PhCH2OCH2CH2
14023PhCH2O(C═O)CH2CH2
14024o-CH3Ph
14025m-CH3Ph
14026p-CH3Ph
140272,4-(CH3)2Ph
140283,5-(CH3)2Ph
140292,4,6-(CH3)3Ph
14030p-CH3OPh
14031p-CH3CH2OPh
14032p-CH3(CH2)2OPh
14033p-FPh
14034p-ClPh
14035p-BrPh
14036p-IPh
14037p-PhOPh
14038p-PhCH2OPh
14039p-NO2Ph
14040p-CNPh
14041p-CH3SO2Ph
14042
14043
14044
14045
14046
14047
14048
14049
14050
14051
14052
14053
14054
14055
14056
14057
14058
14059
14060
14061
14062
TABLE 15
Compound No.R2
15001CH3
15002CH2CH3
15003(CH2)2CH3
15004CH(CH3)2
15005(CH2)3CH3
15006CH2CH(CH3)2
15007CH(CH3)CH2CH3
15008C(CH3)3
15009(CH2)4CH3
15010(CH2)5CH3
15011(CH2)6CH3
15012(CH2)7CH3
15013(CH2)8CH3
15014cyclopropyl
15015cyclobutyl
15016cyclohexyl
15017Ph
15018PhCH2
15019Ph(CH2)2
15020Ph(CH2)3
15021PhO(CH2)2
15022PhCH2OCH2CH2
15023PhCH2O(C═O)CH2CH2
15024o-CH3Ph
15025m-CH3Ph
15026p-CH3Ph
150272,4-(CH3)2Ph
150283,5-(CH3)2Ph
150292,4,6-(CH3)3Ph
15030p-CH3OPh
15031p-CH3CH2OPh
15032p-CH3(CH2)2OPh
15033p-FPh
15034p-ClPh
15035p-BrPh
15036p-IPh
15037p-PhOPh
15038p-PhCH2OPh
15039p-NO2Ph
15040p-CNPh
15041p-CH3SO2Ph
15042
15043
15044
15045
15046
15047
15048
15049
15050
15051
15052
15053
15054
15055
15056
15057
15058
15059
15060
15061
15062
TABLE 16
Compound No.R2
16001CH3
16002CH2CH3
16003(CH2)2CH3
16004CH(CH3)2
16005(CH2)3CH3
16006CH2CH(CH3)2
16007CH(CH3)CH2CH3
16008C(CH3)3
16009(CH2)4CH3
16010(CH2)5CH3
16011(CH2)6CH3
16012(CH2)7CH3
16013(CH2)8CH3
16014cyclopropyl
16015cyclobutyl
16016cyclohexyl
16017Ph
16018PhCH2
16019Ph(CH2)2
16020Ph(CH2)3
16021PhO(CH2)2
16022PhCH2OCH2CH2
16023PhCH2O(C═O)CH2CH2
16024o-CH3Ph
16025m-CH3Ph
16026p-CH3Ph
160272,4-(CH3)2Ph
160283,5-(CH3)2Ph
160292,4,6-(CH3)3Ph
16030p-CH3OPh
16031p-CH3CH2OPh
16032p-CH3(CH2)2OPh
16033p-FPh
16034p-ClPh
16035p-BrPh
16036p-IPh
16037p-PhOPh
16038p-PhCH2OPh
16039p-NO2Ph
16040p-CNPh
16041p-CH3SO2Ph
16042
16043
16044
16045
16046
16047
16048
16049
16050
16051
16052
16053
16054
16055
16056
16057
16058
16059
16060
16061
16062
TABLE 17
Compound No.R2
17001CH3
17002CH2CH3
17003(CH2)2CH3
17004CH(CH3)2
17005(CH2)3CH3
17006CH2CH(CH3)2
17007CH(CH3)CH2CH3
17008C(CH3)3
17009(CH2)4CH3
17010(CH2)5CH3
17011(CH2)6CH3
17012(CH2)7CH3
17013(CH2)8CH3
17014cyclopropyl
17015cyclobutyl
17016cyclohexyl
17017Ph
17018PhCH2
17019Ph(CH2)2
17020Ph(CH2)3
17021PhO(CH2)2
17022PhCH2OCH2CH2
17023PhCH2O(C═O)CH2CH2
17024o-CH3Ph
17025m-CH3Ph
17026p-CH3Ph
170272,4-(CH3)2Ph
170283,5-(CH3)2Ph
170292,4,6-(CH3)3Ph
17030p-CH3OPh
17031p-CH3CH2OPh
17032p-CH3(CH2)2OPh
17033p-FPh
17034p-ClPh
17035p-BrPh
17036p-IPh
17037p-PhOPh
17038p-PhCH2OPh
17039p-NO2Ph
17040p-CNPh
17041p-CH3SO2Ph
17042
17043
17044
17045
17046
17047
17048
17049
17050
17051
17052
17053
17054
17055
17056
17057
17058
17059
17060
17061
17062
TABLE 18
Compound No.R2
18001CH3
18002CH2CH3
18003(CH2)2CH3
18004CH(CH3)2
18005(CH2)3CH3
18006CH2CH(CH3)2
18007CH(CH3)CH2CH3
18008C(CH3)3
18009(CH2)4CH3
18010(CH2)5CH3
18011(CH2)6CH3
18012(CH2)7CH3
18013(CH2)8CH3
18014cyclopropyl
18015cyclobutyl
18016cyclohexyl
18017Ph
18018PhCH2
18019Ph(CH2)2
18020Ph(CH2)3
18021PhO(CH2)2
18022PhCH2OCH2CH2
18023PhCH2O(C═O)CH2CH2
18024o-CH3Ph
18025m-CH3Ph
18026p-CH3Ph
180272,4-(CH3)2Ph
180283,5-(CH3)2Ph
180292,4,6-(CH3)3Ph
18030p-CH3OPh
18031p-CH3CH2OPh
18032p-CH3(CH2)2OPh
18033p-FPh
18034p-ClPh
18035p-BrPh
18036p-IPh
18037p-PhOPh
18038p-PhCH2OPh
18039p-NO2Ph
18040p-CNPh
18041p-CH3SO2Ph
18042
18043
18044
18045
18046
18047
18048
18049
18050
18051
18052
18053
18054
18055
18056
18057
18058
18059
18060
18061
18062
TABLE 19
Compound No.R2
19001CH3
19002CH2CH3
19003(CH2)2CH3
19004CH(CH3)2
19005(CH2)3CH3
19006CH2CH(CH3)2
19007CH(CH3)CH2CH3
19008C(CH3)3
19009(CH2)4CH3
19010(CH2)5CH3
19011(CH2)6CH3
19012(CH2)7CH3
19013(CH2)8CH3
19014cyclopropyl
19015cyclobutyl
19016cyclohexyl
19017Ph
19018PhCH2
19019Ph(CH2)2
19020Ph(CH2)3
19021PhO(CH2)2
19022PhCH2OCH2CH2
19023PhCH2O(C═O)CH2CH2
19024o-CH3Ph
19025m-CH3Ph
19026p-CH3Ph
190272,4-(CH3)2Ph
190283,5-(CH3)2Ph
190292,4,6-(CH3)3Ph
19030p-CH3OPh
19031p-CH3CH2OPh
19032p-CH3(CH2)2OPh
19033p-FPh
19034p-ClPh
19035p-BrPh
19036p-IPh
19037p-PhOPh
19038p-PhCH2OPh
19039p-NO2Ph
19040p-CNPh
19041p-CH3SO2Ph
19042
19043
19044
19045
19046
19047
19048
19049
19050
19051
19052
19053
19054
19055
19056
19057
19058
19059
19060
19061
19062
TABLE 20
Compound No.R2
20001CH3
20002CH2CH3
20003(CH2)2CH3
20004CH(CH3)2
20005(CH2)3CH3
20006CH2CH(CH3)2
20007CH(CH3)CH2CH3
20008C(CH3)3
20009(CH2)4CH3
20010(CH2)5CH3
20011(CH2)6CH3
20012(CH2)7CH3
20013(CH2)8CH3
20014cyclopropyl
20015cyclobutyl
20016cyclohexyl
20017Ph
20018PhCH2
20019Ph(CH2)2
20020Ph(CH2)3
20021PhO(CH2)2
20022PhCH2OCH2CH2
20023PhCH2O(C═O)CH2CH2
20024o-CH3Ph
20025m-CH3Ph
20026p-CH3Ph
200272,4-(CH3)2Ph
200283,5-(CH3)2Ph
200292,4,6-(CH3)3Ph
20030p-CH3OPh
20031p-CH3CH2OPh
20032p-CH3(CH2)2OPh
20033p-FPh
20034p-ClPh
20035p-BrPh
20036p-IPh
20037p-PhOPh
20038p-PhCH2OPh
20039p-NO2Ph
20040p-CNPh
20041p-CH3SO2Ph
20042
20043
20044
20045
20046
20047
20048
20049
20050
20051
20052
20053
20054
20055
20056
20057
20058
20059
20060
20061
20062
TABLE 21
Compound No.R2
21001CH3
21002CH2CH3
21003(CH2)2CH3
21004CH(CH3)2
21005(CH2)3CH3
21006CH2CH(CH3)2
21007CH(CH3)CH2CH3
21008C(CH3)3
21009(CH2)4CH3
21010(CH2)5CH3
21011(CH2)6CH3
21012(CH2)7CH3
21013(CH2)8CH3
21014cyclopropyl
21015cyclobutyl
21016cyclohexyl
21017Ph
21018PhCH2
21019Ph(CH2)2
21020Ph(CH2)3
21021PhO(CH2)2
21022PhCH2OCH2CH2
21023PhCH2O(C═O)CH2CH2
21024o-CH3Ph
21025m-CH3Ph
21026p-CH3Ph
210272,4-(CH3)2Ph
210283,5-(CH3)2Ph
210292,4,6-(CH3)3Ph
21030p-CH3OPh
21031p-CH3CH2OPh
21032p-CH3(CH2)2OPh
21033p-FPh
21034p-ClPh
21035p-BrPh
21036p-IPh
21037p-PhOPh
21038p-PhCH2OPh
21039p-NO2Ph
21040p-CNPh
21041p-CH3SO2Ph
21042
21043
21044
21045
21046
21047
21048
21049
21050
21051
21052
21053
21054
21055
21056
21057
21058
21059
21060
21061
21062
TABLE 22
Compound No.R2
22001CH3
22002CH2CH3
22003(CH2)2CH3
22004CH(CH3)2
22005(CH2)3CH3
22006CH2CH(CH3)2
22007CH(CH3)CH2CH3
22008C(CH3)3
22009(CH2)4CH3
22010(CH2)5CH3
22011(CH2)6CH3
22012(CH2)7CH3
22013(CH2)8CH3
22014cyclopropyl
22015cyclobutyl
22016cyclohexyl
22017Ph
22018PhCH2
22019Ph(CH2)2
22020Ph(CH2)3
22021PhO(CH2)2
22022PhCH2OCH2CH2
22023PhCH2O(C═O)CH2CH2
22024o-CH3Ph
22025m-CH3Ph
22026p-CH3Ph
220272,4-(CH3)2Ph
220283,5-(CH3)2Ph
220292,4,6-(CH3)3Ph
22030p-CH3OPh
22031p-CH3CH2OPh
22032p-CH3(CH2)2OPh
22033p-FPh
22034p-ClPh
22035p-BrPh
22036p-IPh
22037p-PhOPh
22038p-PhCH2OPh
22039p-NO2Ph
22040p-CNPh
22041p-CH3SO2Ph
22042
22043
22044
22045
22046
22047
22048
22049
22050
22051
22052
22053
22054
22055
22056
22057
22058
22059
22060
22061
22062
TABLE 23
Compound No.R2
23001CH3
23002CH2CH3
23003(CH2)2CH3
23004CH(CH3)2
23005(CH2)3CH3
23006CH2CH(CH3)2
23007CH(CH3)CH2CH3
23008C(CH3)3
23009(CH2)4CH3
23010(CH2)5CH3
23011(CH2)6CH3
23012(CH2)7CH3
23013(CH2)8CH3
23014cyclopropyl
23015cyclobutyl
23016cyclohexyl
23017Ph
23018PhCH2
23019Ph(CH2)2
23020Ph(CH2)3
23021PhO(CH2)2
23022PhCH2OCH2CH2
23023PhCH2O(C═O)CH2CH2
23024o-CH3Ph
23025m-CH3Ph
23026p-CH3Ph
230272,4-(CH3)2Ph
230283,5-(CH3)2Ph
230292,4,6-(CH3)3Ph
23030p-CH3OPh
23031p-CH3CH2OPh
23032p-CH3(CH2)2OPh
23033p-FPh
23034p-ClPh
23035p-BrPh
23036p-IPh
23037p-PhOPh
23038p-PhCH2OPh
23039p-NO2Ph
23040p-CNPh
23041p-CH3SO2Ph
23042
23043
23044
23045
23046
23047
23048
23049
23050
23051
23052
23053
23054
23055
23056
23057
23058
23059
23060
23061
23062
TABLE 24
Compound No.R2
24001CH3
24002CH2CH3
24003(CH2)2CH3
24004CH(CH3)2
24005(CH2)3CH3
24006CH2CH(CH3)2
24007CH(CH3)CH2CH3
24008C(CH3)3
24009(CH2)4CH3
24010(CH2)5CH3
24011(CH2)6CH3
24012(CH2)7CH3
24013(CH2)8CH3
24014cyclopropyl
24015cyclobutyl
24016cyclohexyl
24017Ph
24018PhCH2
24019Ph(CH2)2
24020Ph(CH2)3
24021PhO(CH2)2
24022PhCH2OCH2CH2
24023PhCH2O(C═O)CH2CH2
24024o-CH3Ph
24025m-CH3Ph
24026p-CH3Ph
240272,4-(CH3)2Ph
240283,5-(CH3)2Ph
240292,4,6-(CH3)3Ph
24030p-CH3OPh
24031p-CH3CH2OPh
24032p-CH3(CH2)2OPh
24033p-FPh
24034p-ClPh
24035p-BrPh
24036p-IPh
24037p-PhOPh
24038p-PhCH2OPh
24039p-NO2Ph
24040p-CNPh
24041p-CH3SO2Ph
24042
24043
24044
24045
24046
24047
24048
24049
24050
24051
24052
24053
24054
24055
24056
24057
24058
24059
24060
24061
24062
TABLE 25
Compound No.R2
25001CH3
25002CH2CH3
25003(CH2)2CH3
25004CH(CH3)2
25005(CH2)3CH3
25006CH2CH(CH3)2
25007CH(CH3)CH2CH3
25008C(CH3)3
25009(CH2)4CH3
25010(CH2)5CH3
25011(CH2)6CH3
25012(CH2)7CH3
25013(CH2)8CH3
25014cyclopropyl
25015cyclobutyl
25016cyclohexyl
25017Ph
25018PhCH2
25019Ph(CH2)2
25020Ph(CH2)3
25021PhO(CH2)2
25022PhCH2OCH2CH2
25023PhCH2O(C═O)CH2CH2
25024o-CH3Ph
25025m-CH3Ph
25026p-CH3Ph
250272,4-(CH3)2Ph
250283,5-(CH3)2Ph
250292,4,6-(CH3)3Ph
25030p-CH3OPh
25031p-CH3CH2OPh
25032p-CH3(CH2)2OPh
25033p-FPh
25034p-ClPh
25035p-BrPh
25036p-IPh
25037p-PhOPh
25038p-PhCH2OPh
25039p-NO2Ph
25040p-CNPh
25041p-CH3SO2Ph
25042
25043
25044
25045
25046
25047
25048
25049
25050
25051
25052
25053
25054
25055
25056
25057
25058
25059
25060
25061
25062
TABLE 26
Compound No.R2
26001CH3
26002CH2CH3
26003(CH2)2CH3
26004CH(CH3)2
26005(CH2)3CH3
26006CH2CH(CH3)2
26007CH(CH3)CH2CH3
26008C(CH3)3
26009(CH2)4CH3
26010(CH2)5CH3
26011(CH2)6CH3
26012(CH2)7CH3
26013(CH2)8CH3
26014cyclopropyl
26015cyclobutyl
26016cyclohexyl
26017Ph
26018PhCH2
26019Ph(CH2)2
26020Ph(CH2)3
26021PhO(CH2)2
26022PhCH2OCH2CH2
26023PhCH2O(C═O)CH2CH2
26024o-CH3Ph
26025m-CH3Ph
26026p-CH3Ph
260272,4-(CH3)2Ph
260283,5-(CH3)2Ph
260292,4,6-(CH3)3Ph
26030p-CH3OPh
26031p-CH3CH2OPh
26032p-CH3(CH2)2OPh
26033p-FPh
26034p-ClPh
26035p-BrPh
26036p-IPh
26037p-PhOPh
26038p-PhCH2OPh
26039p-NO2Ph
26040p-CNPh
26041p-CH3SO2Ph
26042
26043
26044
26045
26046
26047
26048
26049
26050
26051
26052
26053
26054
26055
26056
26057
26058
26059
26060
26061
26062
TABLE 27
Compound No.R2
27001CH3
27002CH2CH3
27003(CH2)2CH3
27004CH(CH3)2
27005(CH2)3CH3
27006CH2CH(CH3)2
27007CH(CH3)CH2CH3
27008C(CH3)3
27009(CH2)4CH3
27010(CH2)5CH3
27011(CH2)6CH3
27012(CH2)7CH3
27013(CH2)8CH3
27014cyclopropyl
27015cyclobutyl
27016cyclohexyl
27017Ph
27018PhCH2
27019Ph(CH2)2
27020Ph(CH2)3
27021PhO(CH2)2
27022PhCH2OCH2CH2
27023PhCH2O(C═O)CH2CH2
27024o-CH3Ph
27025m-CH3Ph
27026p-CH3Ph
270272,4-(CH3)2Ph
270283,5-(CH3)2Ph
270292,4,6-(CH3)3Ph
27030p-CH3OPh
27031p-CH3CH2OPh
27032p-CH3(CH2)2OPh
27033p-FPh
27034p-ClPh
27035p-BrPh
27036p-IPh
27037p-PhOPh
27038p-PhCH2OPh
27039p-NO2Ph
27040p-CNPh
27041p-CH3SO2Ph
27042
27043
27044
27045
27046
27047
27048
27049
27050
27051
27052
27053
27054
27055
27056
27057
27058
27059
27060
27061
27062
TABLE 28
Compound No.R2
28001CH3
28002CH2CH3
28003(CH2)2CH3
28004CH(CH3)2
28005(CH2)3CH3
28006CH2CH(CH3)2
28007CH(CH3)CH2CH3
28008C(CH3)3
28009(CH2)4CH3
28010(CH2)5CH3
28011(CH2)6CH3
28012(CH2)7CH3
28013(CH2)8CH3
28014cyclopropyl
28015cyclobutyl
28016cyclohexyl
28017Ph
28018PhCH2
28019Ph(CH2)2
28020Ph(CH2)3
28021PhO(CH2)2
28022PhCH2OCH2CH2
28023PhCH2O(C═O)CH2CH2
28024o-CH3Ph
28025m-CH3Ph
28026p-CH3Ph
280272,4-(CH3)2Ph
280283,5-(CH3)2Ph
280292,4,6-(CH3)3Ph
28030p-CH3OPh
28031p-CH3CH2OPh
28032p-CH3(CH2)2OPh
28033p-FPh
28034p-ClPh
28035p-BrPh
28036p-IPh
28037p-PhOPh
28038p-PhCH2OPh
28039p-NO2Ph
28040p-CNPh
28041p-CH3SO2Ph
28042
28043
28044
28045
28046
28047
28048
28049
28050
28051
28052
28053
28054
28055
28056
28057
28058
28059
28060
28061
28062
TABLE 29
Compound No.R2
29001CH3
29002CH2CH3
29003(CH2)2CH3
29004CH(CH3)2
29005(CH2)3CH3
29006CH2CH(CH3)2
29007CH(CH3)CH2CH3
29008C(CH3)3
29009(CH2)4CH3
29010(CH2)5CH3
29011(CH2)6CH3
29012(CH2)7CH3
29013(CH2)8CH3
29014cyclopropyl
29015cyclobutyl
29016cyclohexyl
29017Ph
29018PhCH2
29019Ph(CH2)2
29020Ph(CH2)3
29021PhO(CH2)2
29022PhCH2OCH2CH2
29023PhCH2O(C═O)CH2CH2
29024o-CH3Ph
29025m-CH3Ph
29026p-CH3Ph
290272,4-(CH3)2Ph
290283,5-(CH3)2Ph
290292,4,6-(CH3)3Ph
29030p-CH3OPh
29031p-CH3CH2OPh
29032p-CH3(CH2)2OPh
29033p-FPh
29034p-ClPh
29035p-BrPh
29036p-IPh
29037p-PhOPh
29038p-PhCH2OPh
29039p-NO2Ph
29040p-CNPh
29041p-CH3SO2Ph
29042
29043
29044
29045
29046
29047
29048
29049
29050
29051
29052
29053
29054
29055
29056
29057
29058
29059
29060
29061
29062
TABLE 30
Compound No.R2
30001CH3
30002CH2CH3
30003(CH2)2CH3
30004CH(CH3)2
30005(CH2)3CH3
30006CH2CH(CH3)2
30007CH(CH3)CH2CH3
30008C(CH3)3
30009(CH2)4CH3
30010(CH2)5CH3
30011(CH2)6CH3
30012(CH2)7CH3
30013(CH2)8CH3
30014cyclopropyl
30015cyclobutyl
30016cyclohexyl
30017Ph
30018PhCH2
30019Ph(CH2)2
30020Ph(CH2)3
30021PhO(CH2)2
30022PhCH2OCH2CH2
30023PhCH2O(C═O)CH2CH2
30024o-CH3Ph
30025m-CH3Ph
30026p-CH3Ph
300272,4-(CH3)2Ph
300283,5-(CH3)2Ph
300292,4,6-(CH3)3Ph
30030p-CH3OPh
30031p-CH3CH2OPh
30032p-CH3(CH2)2OPh
30033p-FPh
30034p-ClPh
30035p-BrPh
30036p-IPh
30037p-PhOPh
30038p-PhCH2OPh
30039p-NO2Ph
30040p-CNPh
30041p-CH3SO2Ph
30042
30043
30044
30045
30046
30047
30048
30049
30050
30051
30052
30053
30054
30055
30056
30057
30058
30059
30060
30061
30062
TABLE 31
Compound No.R2
31001CH3
31002CH2CH3
31003(CH2)2CH3
31004CH(CH3)2
31005(CH2)3CH3
31006CH2CH(CH3)2
31007CH(CH3)CH2CH3
31008C(CH3)3
31009(CH2)4CH3
31010(CH2)5CH3
31011(CH2)6CH3
31012(CH2)7CH3
31013(CH2)8CH3
31014cyclopropyl
31015cyclobutyl
31016cyclohexyl
31017Ph
31018PhCH2
31019Ph(CH2)2
31020Ph(CH2)3
31021PhO(CH2)2
31022PhCH2OCH2CH2
31023PhCH2O(C═O)CH2CH2
31024o-CH3Ph
31025m-CH3Ph
31026p-CH3Ph
310272,4-(CH3)2Ph
310283,5-(CH3)2Ph
310292,4,6-(CH3)3Ph
31030p-CH3OPh
31031p-CH3CH2OPh
31032p-CH3(CH2)2OPh
31033p-FPh
31034p-ClPh
31035p-BrPh
31036p-IPh
31037p-PhOPh
31038p-PhCH2OPh
31039p-NO2Ph
31040p-CNPh
31041p-CH3SO2Ph
31042
31043
31044
31045
31046
31047
31048
31049
31050
31051
31052
31053
31054
31055
31056
31057
31058
31059
31060
31061
31062
TABLE 32
Compound No.R2
32001CH3
32002CH2CH3
32003(CH2)2CH3
32004CH(CH3)2
32005(CH2)3CH3
32006CH2CH(CH3)2
32007CH(CH3)CH2CH3
32008C(CH3)3
32009(CH2)4CH3
32010(CH2)5CH3
32011(CH2)6CH3
32012(CH2)7CH3
32013(CH2)8CH3
32014cyclopropyl
32015cyclobutyl
32016cyclohexyl
32017Ph
32018PhCH2
32019Ph(CH2)2
32020Ph(CH2)3
32021PhO(CH2)2
32022PhCH2OCH2CH2
32023PhCH2O(C═O)CH2CH2
32024o-CH3Ph
32025m-CH3Ph
32026p-CH3Ph
320272,4-(CH3)2Ph
320283,5-(CH3)2Ph
320292,4,6-(CH3)3Ph
32030p-CH3OPh
32031p-CH3CH2OPh
32032p-CH3(CH2)2OPh
32033p-FPh
32034p-ClPh
32035p-BrPh
32036p-IPh
32037p-PhOPh
32038p-PhCH2OPh
32039p-NO2Ph
32040p-CNPh
32041p-CH3SO2Ph
32042
32043
32044
32045
32046
32047
32048
32049
32050
32051
32052
32053
32054
32055
32056
32057
32058
32059
32060
32061
32062
TABLE 33
Compound No.R2
33001CH3
33002CH2CH3
33003(CH2)2CH3
33004CH(CH3)2
33005(CH2)3CH3
33006CH2CH(CH3)2
33007CH(CH3)CH2CH3
33008C(CH3)3
33009(CH2)4CH3
33010(CH2)5CH3
33011(CH2)6CH3
33012(CH2)7CH3
33013(CH2)8CH3
33014cyclopropyl
33015cyclobutyl
33016cyclohexyl
33017Ph
33018PhCH2
33019Ph(CH2)2
33020Ph(CH2)3
33021PhO(CH2)2
33022PhCH2OCH2CH2
33023PhCH2O(C═O)CH2CH2
33024o-CH3Ph
33025m-CH3Ph
33026p-CH3Ph
330272,4-(CH3)2Ph
330283,5-(CH3)2Ph
330292,4,6-(CH3)3Ph
33030p-CH3OPh
33031p-CH3CH2OPh
33032p-CH3(CH2)2OPh
33033p-FPh
33034p-ClPh
33035p-BrPh
33036p-IPh
33037p-PhOPh
33038p-PhCH2OPh
33039p-NO2Ph
33040p-CNPh
33041p-CH3SO2Ph
33042
33043
33044
33045
33046
33047
33048
33049
33050
33051
33052
33053
33054
33055
33056
33057
33058
33059
33060
33061
33062
TABLE 34
Compound No.R2
34001CH3
34002CH2CH3
34003(CH2)2CH3
34004CH(CH3)2
34005(CH2)3CH3
34006CH2CH(CH3)2
34007CH(CH3)CH2CH3
34008C(CH3)3
34009(CH2)4CH3
34010(CH2)5CH3
34011(CH2)6CH3
34012(CH2)7CH3
34013(CH2)8CH3
34014cyclopropyl
34015cyclobutyl
34016cyclohexyl
34017Ph
34018PhCH2
34019Ph(CH2)2
34020Ph(CH2)3
34021PhO(CH2)2
34022PhCH2OCH2CH2
34023PhCH2O(C═O)CH2CH2
34024o-CH3Ph
34025m-CH3Ph
34026p-CH3Ph
340272,4-(CH3)2Ph
340283,5-(CH3)2Ph
340292,4,6-(CH3)3Ph
34030p-CH3OPh
34031p-CH3CH2OPh
34032p-CH3(CH2)2OPh
34033p-FPh
34034p-ClPh
34035p-BrPh
34036p-IPh
34037p-PhOPh
34038p-PhCH2OPh
34039p-NO2Ph
34040p-CNPh
34041p-CH3SO2Ph
34042
34043
34044
34045
34046
34047
34048
34049
34050
34051
34052
34053
34054
34055
34056
34057
34058
34059
34060
34061
34062
TABLE 35
Compound No.R2
35001CH3
35002CH2CH3
35003(CH2)2CH3
35004CH(CH3)2
35005(CH2)3CH3
35006CH2CH(CH3)2
35007CH(CH3)CH2CH3
35008C(CH3)3
35009(CH2)4CH3
35010(CH2)5CH3
35011(CH2)6CH3
35012(CH2)7CH3
35013(CH2)8CH3
35014cyclopropyl
35015cyclobutyl
35016cyclohexyl
35017Ph
35018PhCH2
35019Ph(CH2)2
35020Ph(CH2)3
35021PhO(CH2)2
35022PhCH2OCH2CH2
35023PhCH2O(C═O)CH2CH2
35024o-CH3Ph
35025m-CH3Ph
35026p-CH3Ph
350272,4-(CH3)2Ph
350283,5-(CH3)2Ph
350292,4,6-(CH3)3Ph
35030p-CH3OPh
35031p-CH3CH2OPh
35032p-CH3(CH2)2OPh
35033p-FPh
35034p-ClPh
35035p-BrPh
35036p-IPh
35037p-PhOPh
35038p-PhCH2OPh
35039p-NO2Ph
35040p-CNPh
35041p-CH3SO2Ph
35042
35043
35044
35045
35046
35047
35048
35049
35050
35051
35052
35053
35054
35055
35056
35057
35058
35059
35060
35061
35062
TABLE 36
Compound No.R2
36001CH3
36002CH2CH3
36003(CH2)2CH3
36004CH(CH3)2
36005(CH2)3CH3
36006CH2CH(CH3)2
36007CH(CH3)CH2CH3
36008C(CH3)3
36009(CH2)4CH3
36010(CH2)5CH3
36011(CH2)6CH3
36012(CH2)7CH3
36013(CH2)8CH3
36014cyclopropyl
36015cyclobutyl
36016cyclohexyl
36017Ph
36018PhCH2
36019Ph(CH2)2
36020Ph(CH2)3
36021PhO(CH2)2
36022PhCH2OCH2CH2
36023PhCH2O(C═O)CH2CH2
36024o-CH3Ph
36025m-CH3Ph
36026p-CH3Ph
360272,4-(CH3)2Ph
360283,5-(CH3)2Ph
360292,4,6-(CH3)3Ph
36030p-CH3OPh
36031p-CH3CH2OPh
36032p-CH3(CH2)2OPh
36033p-FPh
36034p-ClPh
36035p-BrPh
36036p-IPh
36037p-PhOPh
36038p-PhCH2OPh
36039p-NO2Ph
36040p-CNPh
36041p-CH3SO2Ph
36042
36043
36044
36045
36046
36047
36048
36049
36050
36051
36052
36053
36054
36055
36056
36057
36058
36059
36060
36061
36062
TABLE 37
Compound No.R2
37001CH3
37002CH2CH3
37003(CH2)2CH3
37004CH(CH3)2
37005(CH2)3CH3
37006CH2CH(CH3)2
37007CH(CH3)CH2CH3
37008C(CH3)3
37009(CH2)4CH3
37010(CH2)5CH3
37011(CH2)6CH3
37012(CH2)7CH3
37013(CH2)8CH3
37014cyclopropyl
37015cyclobutyl
37016cyclohexyl
37017Ph
37018PhCH2
37019Ph(CH2)2
37020Ph(CH2)3
37021PhO(CH2)2
37022PhCH2OCH2CH2
37023PhCH2O(C═O)CH2CH2
37024o-CH3Ph
37025m-CH3Ph
37026p-CH3Ph
370272,4-(CH3)2Ph
370283,5-(CH3)2Ph
370292,4,6-(CH3)3Ph
37030p-CH3OPh
37031p-CH3CH2OPh
37032p-CH3(CH2)2OPh
37033p-FPh
37034p-ClPh
37035p-BrPh
37036p-IPh
37037p-PhOPh
37038p-PhCH2OPh
37039p-NO2Ph
37040p-CNPh
37041p-CH3SO2Ph
37042
37043
37044
37045
37046
37047
37048
37049
37050
37051
37052
37053
37054
37055
37056
37057
37058
37059
37060
37061
37062
TABLE 38
Compound No.R2
38001CH3
38002CH2CH3
38003(CH2)2CH3
38004CH(CH3)2
38005(CH2)3CH3
38006CH2CH(CH3)2
38007CH(CH3)CH2CH3
38008C(CH3)3
38009(CH2)4CH3
38010(CH2)5CH3
38011(CH2)6CH3
38012(CH2)7CH3
38013(CH2)8CH3
38014cyclopropyl
38015cyclobutyl
38016cyclohexyl
38017Ph
38018PhCH2
38019Ph(CH2)2
38020Ph(CH2)3
38021PhO(CH2)2
38022PhCH2OCH2CH2
38023PhCH2O(C═O)CH2CH2
38024o-CH3Ph
38025m-CH3Ph
38026p-CH3Ph
380272,4-(CH3)2Ph
380283,5-(CH3)2Ph
380292,4,6-(CH3)3Ph
38030p-CH3OPh
38031p-CH3CH2OPh
38032p-CH3(CH2)2OPh
38033p-FPh
38034p-ClPh
38035p-BrPh
38036p-IPh
38037p-PhOPh
38038p-PhCH2OPh
38039p-NO2Ph
38040p-CNPh
38041p-CH3SO2Ph
38042
38043
38044
38045
38046
38047
38048
38049
38050
38051
38052
38053
38054
38055
38056
38057
38058
38059
38060
38061
38062
TABLE 39
Compound No.R2
39001CH3
39002CH2CH3
39003(CH2)2CH3
39004CH(CH3)2
39005(CH2)3CH3
39006CH2CH(CH3)2
39007CH(CH3)CH2CH3
39008C(CH3)3
39009(CH2)4CH3
39010(CH2)5CH3
39011(CH2)6CH3
39012(CH2)7CH3
39013(CH2)8CH3
39014cyclopropyl
39015cyclobutyl
39016cyclohexyl
39017Ph
39018PhCH2
39019Ph(CH2)2
39020Ph(CH2)3
39021PhO(CH2)2
39022PhCH2OCH2CH2
39023PhCH2O(C═O)CH2CH2
39024o-CH3Ph
39025m-CH3Ph
39026p-CH3Ph
390272,4-(CH3)2Ph
390283,5-(CH3)2Ph
390292,4,6-(CH3)3Ph
39030p-CH3OPh
39031p-CH3CH2OPh
39032p-CH3(CH2)2OPh
39033p-FPh
39034p-ClPh
39035p-BrPh
39036p-IPh
39037p-PhOPh
39038p-PhCH2OPh
39039p-NO2Ph
39040p-CNPh
39041p-CH3SO2Ph
39042
39043
39044
39045
39046
39047
39048
39049
39050
39051
39052
39053
39054
39055
39056
39057
39058
39059
39060
39061
39062
TABLE 40
Compound No.R2
40001CH3
40002CH2CH3
40003(CH2)2CH3
40004CH(CH3)2
40005(CH2)3CH3
40006CH2CH(CH3)2
40007CH(CH3)CH2CH3
40008C(CH3)3
40009(CH2)4CH3
40010(CH2)5CH3
40011(CH2)6CH3
40012(CH2)7CH3
40013(CH2)8CH3
40014cyclopropyl
40015cyclobutyl
40016cyclohexyl
40017Ph
40018PhCH2
40019Ph(CH2)2
40020Ph(CH2)3
40021PhO(CH2)2
40022PhCH2OCH2CH2
40023PhCH2O(C═O)CH2CH2
40024o-CH3Ph
40025m-CH3Ph
40026p-CH3Ph
400272,4-(CH3)2Ph
400283,5-(CH3)2Ph
400292,4,6-(CH3)3Ph
40030p-CH3OPh
40031p-CH3CH2OPh
40032p-CH3(CH2)2OPh
40033p-FPh
40034p-ClPh
40035p-BrPh
40036p-IPh
40037p-PhOPh
40038p-PhCH2OPh
40039p-NO2Ph
40040p-CNPh
40041p-CH3SO2Ph
40042
40043
40044
40045
40046
40047
40048
40049
40050
40051
40052
40053
40054
40055
40056
40057
40058
40059
40060
40061
40062
TABLE 41
Compound No.R2Compound No.R2
41001CH341045
41002CH2CH341046
41003(CH2)2CH341047
41004CH(CH3)241048
41005(CH2)3CH341049
41006CH2CH(CH3)241050
41007CH(CH3)CH2CH341051
41008C(CH3)341052
41009(CH2)4CH341053
41010(CH2)5CH341054
41011(CH2)6CH341055
41012(CH2)7CH341056
41013(CH2)8CH341057
41014cyclopropyl41058
41015cyclobutyl41059
41016cyclohexyl41060
41017Ph41061
41018PhCH241062
41019Ph(CH2)2
41020Ph(CH2)3
41021PhO(CH2)2
41022PhCH2OCH2CH2
41023PhCH2O(C═O)CH2CH2
41024o-CH3Ph
41025m-CH3Ph
41026p-CH3Ph
410272,4-(CH3)2Ph
410283,5-(CH3)2Ph
410292,4,6(CH3)3Ph
41030p-CH3OPh
41031p-CH3CH2OPh
41032p-CH3(CH2)2OPh
41033p-FPh
41034p-ClPh
41035p-BrPh
41036p-IPh
41037p-PhOPh
41038p-PhCH2OPh
41039p-NO2Ph
41040p-CNPh
41041p-CH3SO2Ph
41042
41043
41044
TABLE 42
Compound No.R2Compound No.R2
42001CH342045
42002CH2CH342046
42003(CH2)2CH342047
42004CH(CH3)242048
42005(CH2)3CH342049
42006CH2CH(CH3)242050
42007CH(CH3)CH2CH342051
42008C(CH3)342052
42009(CH2)4CH342053
42010(CH2)5CH342054
42011(CH2)6CH342055
42012(CH2)7CH342056
42013(CH2)8CH342057
42014cyclopropyl42058
42015cyclobutyl42059
42016cyclohexyl42060
42017Ph42061
42018PhCH242062
42019Ph(CH2)2
42020Ph(CH2)3
42021PhO(CH2)2
42022PhCH2OCH2CH2
42023PhCH2O(C═O)CH2CH2
42024o-CH3Ph
42025m-CH3Ph
42026p-CH3Ph
420272,4-(CH3)2Ph
420283,5-(CH3)2Ph
420292,4,6(CH3)3Ph
42030p-CH3OPh
42031p-CH3CH2OPh
42032p-CH3(CH2)2OPh
42033p-FPh
42034p-ClPh
42035p-BrPh
42036p-IPh
42037p-PhOPh
42038p-PhCH2OPh
42039p-NO2Ph
42040p-CNPh
42041p-CH3SO2Ph
42042
42043
42044
TABLE 43
Compound No.R2Compound No.R2
43001CH343045
43002CH2CH343046
43003(CH2)2CH343047
43004CH(CH3)243048
43005(CH2)3CH343049
43006CH2CH(CH3)243050
43007CH(CH3)CH2CH343051
43008C(CH3)343052
43009(CH2)4CH343053
43010(CH2)5CH343054
43011(CH2)6CH343055
43012(CH2)7CH343056
43013(CH2)8CH343057
43014cyclopropyl43058
43015cyclobutyl43059
43016cyclohexyl43060
43017Ph43061
43018PhCH243062
43019Ph(CH2)2
43020Ph(CH2)3
43021PhO(CH2)2
43022PhCH2OCH2CH2
43023PhCH2O(C═O)CH2CH2
43024o-CH3Ph
43025m-CH3Ph
43026p-CH3Ph
430272,4-(CH3)2Ph
430283,5-(CH3)2Ph
430292,4,6(CH3)3Ph
43030p-CH3OPh
43031p-CH3CH2OPh
43032p-CH3(CH2)2OPh
43033p-FPh
43034p-ClPh
43035p-BrPh
43036p-IPh
43037p-PhOPh
43038p-PhCH2OPh
43039p-NO2Ph
43040p-CNPh
43041p-CH3SO2Ph
43042
43043
43044
TABLE 44
Compound No.R2Compound No.R2
44001CH344045
44002CH2CH344046
44003(CH2)2CH344047
44004CH(CH3)244048
44005(CH2)3CH344049
44006CH2CH(CH3)244050
44007CH(CH3)CH2CH344051
44008C(CH3)344052
44009(CH2)4CH344053
44010(CH2)5CH344054
44011(CH2)6CH344055
44012(CH2)7CH344056
44013(CH2)8CH344057
44014cyclopropyl44058
44015cyclobutyl44059
44016cyclohexyl44060
44017Ph44061
44018PhCH244062
44019Ph(CH2)2
44020Ph(CH2)3
44021PhO(CH2)2
44022PhCH2OCH2CH2
44023PhCH2O(C═O)CH2CH2
44024o-CH3Ph
44025m-CH3Ph
44026p-CH3Ph
440272,4-(CH3)2Ph
440283,5-(CH3)2Ph
440292,4,6(CH3)3Ph
44030p-CH3OPh
44031p-CH3CH2OPh
44032p-CH3(CH2)2OPh
44033p-FPh
44034p-ClPh
44035p-BrPh
44036p-IPh
44037p-PhOPh
44038p-PhCH2OPh
44039p-NO2Ph
44040p-CNPh
44041p-CH3SO2Ph
44042
44043
44044
TABLE 45
Compound No.R2Compound No.R2
45001CH345045
45002CH2CH345046
45003(CH2)2CH345047
45004CH(CH3)245048
45005(CH2)3CH345049
45006CH2CH(CH3)245050
45007CH(CH3)CH2CH345051
45008C(CH3)345052
45009(CH2)4CH345053
45010(CH2)5CH345054
45011(CH2)6CH345055
45012(CH2)7CH345056
45013(CH2)8CH345057
45014cyclopropyl45058
45015cyclobutyl45059
45016cyclohexyl45060
45017Ph45061
45018PhCH245062
45019Ph(CH2)2
45020Ph(CH2)3
45021PhO(CH2)2
45022PhCH2OCH2CH2
45023PhCH2O(C═O)CH2CH2
45024o-CH3Ph
45025m-CH3Ph
45026p-CH3Ph
450272,4-(CH3)2Ph
450283,5-(CH3)2Ph
450292,4,6(CH3)3Ph
45030p-CH3OPh
45031p-CH3CH2OPh
45032p-CH3(CH2)2OPh
45033p-FPh
45034p-ClPh
45035p-BrPh
45036p-IPh
45037p-PhOPh
45038p-PhCH2OPh
45039p-NO2Ph
45040p-CNPh
45041p-CH3SO2Ph
45042
45043
45044
TABLE 46
Compound No.R2Compound No.R2
46001CH346045
46002CH2CH346046
46003(CH2)2CH346047
46004CH(CH3)246048
46005(CH2)3CH346049
46006CH2CH(CH3)246050
46007CH(CH3)CH2CH346051
46008C(CH3)346052
46009(CH2)4CH346053
46010(CH2)5CH346054
46011(CH2)6CH346055
46012(CH2)7CH346056
46013(CH2)8CH346057
46014cyclopropyl46058
46015cyclobutyl46059
46016cyclohexyl46060
46017Ph46061
46018PhCH246062
46019Ph(CH2)2
46020Ph(CH2)3
46021PhO(CH2)2
46022PhCH2OCH2CH2
46023PhCH2O(C═O)CH2CH2
46024o-CH3Ph
46025m-CH3Ph
46026p-CH3Ph
460272,4-(CH3)2Ph
460283,5-(CH3)2Ph
460292,4,6(CH3)3Ph
46030p-CH3OPh
46031p-CH3CH2OPh
46032p-CH3(CH2)2OPh
46033p-FPh
46034p-ClPh
46035p-BrPh
46036p-IPh
46037p-PhOPh
46038p-PhCH2OPh
46039p-NO2Ph
46040p-CNPh
46041p-CH3SO2Ph
46042
46043
46044

Claims as granted

9 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

15 codes
IPC · International Patent Classification
Section C — Chemistry; metallurgy
  • C07D413/06
  • C07D521/00
  • C07D417/06
  • C07C237/22
  • C07D487/08
  • C07D263/44
  • C07D295/185
  • C07D417/14
  • C07D413/14
  • C07D471/04
  • C07C231/10
USPC · US Patent Classification
530/323530/335530/334548/226

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomJul 2001Oct 2001Jan 2002Apr 2002Jul 2002Oct 2002Jan 2003Apr 2003Jul 2003Oct 2003Jan 2004USPTOApplicantNon-final rejectionResponse after non-finalNon-final rejectionResponse after non-final
USPTOApplicanthover for detail · click to open
Pendency
2.5 y
909 days filing → grant
Office actions
2
non-final + final
Responses
3
no RCE
Examiner
Alan L. Rotman
art unit 1626 · TC 1600
Citations: 13 back · 1 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom20022004200620082010201220142016201820202022Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock